Platelet inhibitor agents in cardiovascular disease: An update

JACC Vol. 14. NII. October lW:xI3-!~~

813

t

ACC ANNIVERSARY SEMINAR Suzanne

B. Knoebel,

MD, FACC,

Guest

Editor

Platelet Inhibitor Agents in Cardiovascular Disease: An Update BERNARD0

STEIN,

MARC COHEN, JAMES

MD,* VALENTIN

MD, FACC,*

H. CHESEBRO,

FUSTER,

LINA BADIMON,

MD, FACC,*

PHD,* JUAN J. BADIMON,

??

ANNIVERSARY decreases vascular mortality in acute myocar1949-1989 dial infarction. Platelet inhibitors decrease mortality and recurrent cardiovascular events in the chronic phase after myocardial infarction. They also decrease vein graft occlusion rates after coronary bypass surgery. Although platelet inhibitors are beneficial in

In the late 1960s. aspirin was found to have platelet inhibitory effects; its role in the prevention of coronary platelet thrombosis, then considered the cause of heart attacks, was anticipated. During the 197Os,however, the antithrombotic effects of aspirin were viewed with pessimism, mainly because of two factors. First, the role of coronary thrombosis in the pathogenesis of myocardial infarction was questioned. Second, the effects of platelet inhibitors (including aspirin) in the secondary prevention of coronary artery disease did not From the *Division of Cardiology, Mount Sinai Medical Center, New York, New York and the tDivision of Cardiovascular Diseases, Mayo Clinic. Rochester, Minnesota. Address for reorints: Valentin Fuster, MD, Chief, Division of Cardiology, BOX 1030,Mount Sinai Medical Center, One Gustave L. Levy Place, New York

10029.

61989 hy the American

College

MD,*

PHD,*

Minnesotrr

Platelets interact with the coagulation and fibrinolytic systerns in the maintenance of hemostasis. However, these physiologic mechanisms may become pathologic, requiring prevention and treatment. In this review, the following clinical developments are analyzed: 1) the role :Ir’ ; c: of platelets in thrombogenesis; 2) the pharma- - - - - - c cology of platelet inhibitory agents; and, most * * important, 3) the results of recent randomized . 1 s trials of platelet inhibitor agents in different . cardiovascular disorders. ‘w Aspirin reduces mortality and infarction ‘0 I rates in unstable angina and significantly

New

H. ISRAEL,

MD, FACCt

NEW York, New, York und Rochester,

York.

DOUGLAS

of (‘ardiology

preventing acute vessel occlusion during coronary angioplasty, they are ineffective in preventing chronic restenosis. Antiplatelet agents, combined with warfarin, reduce thromboembolic events in patients with a mechanical prosthesis. Platelet inhibitors are also effective .c; in secondary prevention of vascular events in . . patients with cerebrovascular disease. Finally, the use of aspirin for primary prevention of “fh cardiovascular disease is still evolving, partic. ularly in individuals at high risk. . In conclusion, platelet inhibitors are effective in patients with a variety of cardiovascular disorders. The best studied, most inexpensive and least toxic agent is aspirin at a daily dose of 160 to 325 mg. Studies using new platelet inhibitor agents with different mechanisms of action are currently underway. (J Am Co11 Cardiol1989;14:813-36) ??

meet with the expectations of the investigators. In the 198Os, an enthusiastic support for platelet inhibitors, especially aspirin, has reemerged. This renewed interest is a result of a better understanding of the important role of platelets and thrombosis in the pathogenesis of coronary disease. In addition, the results of better designed trials of aspirin in

This article is part of a series of articles celebrating the 40th anniversary of the American College of Cardiology. The series attempts to set the stage for the future by describing current state of the art management of selected major cardiovascular problems and the basic knowledge that will provide directions for advances in diagnosis and therapy. 0735 10971891$3.50

814

STEIN ET AL.

JACC Vol. 14, No. 4 October 1989:813-36

PLATELETINHIBITORAGENTS

patients with coronary disease have lent further support to the use of antiplatelet therapy in unstable angina, acute myocardial infarction, coronary angioplasty and saphenous vein bypass surgery. Furthermore, the role of aspirin in the secondary prevention of coronary and cerebrovascular disease has become apparent and its usefulness in primary prevention is emerging. Platelets are not the only elements involved in thrombotic and thromboembolic processes. These processes result from an interaction between platelets and the coagulation and fibrinolytic systems. We have attempted to analyze: 1) the role of platelets in thrombogenesis, 2) the pharmacology of platelet inhibitor agents, and 3) the results of randomized controlled trials of platelet inhibitors in coronary artery disease, saphenous vein graft disease, prosthetic valve replacement and cerebrovascular disease. A complete discussion of anticoagulant and fibrinolytic therapy is beyond the scope of this review, and has been undertaken elsewhere (1,2). However, specific aspects of anticoagulation and fibrinolysis will be briefly mentioned when pertinent.

PLATELET

ADHESION

Plolcletr

Microhbrils

PLATELET

5 8

ARTERIAL

AGGREGATION

THROMBUS

Role of Platelets in Thrombogenesis Platelets are fragments of membrane-enclosed megakariocytic cytoplasm that travel in the periphery of the circulating mass and do not adhere to intact endothelium. After superficial endothelial injury, only a monolayer of platelets adheres to the exposed subendothelium. When endothelial damage is more severe, exposure of collagen and other elements of the vessel wall stimulates the activation of platelets and the coagulation system and leads to thrombus formation (3). In this section, we will examine the processes of platelet adhesion and spreading, platelet secretion and aggregation and activation of the clotting system, as well as of endogenous inhibitors of thrombosis. Platelet adhesion and spreading. Platelets do not attach to the intact endothelium, but they firmly adhere to a disrupted or damaged endothelial surface (Fig. 1). Subendothelial collagen and fibronectin markedly stimulate platelet adhesion. Platelets adhere more avidly to collagen fibrils that lie deep within the vascular wall, such as in ulcerated atherosclerotic plaques, than to those found immediately beneath the endothelium (4). Platelet membrane receptors are essential in the process of adhesion and aggregation (Fig. 2). Glycoprotein Ia binds collagen at low shear rates and may contribute to platelet adherence to the area of damage. Glycoprotein Ib serves as the binding site for von Willebrand factor, especially at high shear rates (5). Glycoprotein IIbIIIa not only plays an essential role in platelet aggregation by binding fibrinogen and von Willebrand factor, but also participates in the process of adhesion (5). After adhesion, platelets lose their discoid shape, form pseudopods and spread out over the injured surface. Parallel association of actin filaments leads to pseudopod formation,

Figure 1. Schematic representation of the microscopic phases of arterial thrombusformation:platelet adhesionand spreading,platelet aggregation,activation of the coagulationsystem and thrombus formation and activation of the endogenousinhibitorsof thrombosis. Dashedline denotes an inhibitory reaction. ADP = adenosine diphosphate; TxA, = thromboxane A,.

spreading of the platelet surface membrane into a thin film, platelet contraction and stabilization of the hemostatic plug (6). Platelet secretion and aggregation. Platelets contain different types of secretory granules including dense and alpha granules, lysosomes and peroxisomes (Table 1). The first two are particularly important in aggregation and thrombogenesis. Dense granules contain adenosine diphosphate, serotonin, calcium and phosphate. Of these, adenosine diphosphate is the most important proaggregating compound. Alpha granules contain fibrinogen, fibronectin, von Willebrand factor, platelet factor 4, platelet-derived growth factor, thrombospondin and other compounds. Fibrinogen, von Willebrand factor and fibronectin are found not only in platelet granule secretions, but also in plasma. It is not yet known whether the platelet or the plasmatic components are physiologically more important in aggregation. Fibrinogen and von Willebrand factor bind to their receptorglycoprotein IIb-IIIa--on adjacent platelets and form stable platelet aggregates (Fig. 2) (5,7). Platelet-derived growth factor is a potent mitogen and chemotactic agent for smooth

STEIN ETAL. PLATELETINHIBITOR AGENTS

JACC Vol.14.No.4 October 1989:X13-36

815

EXTRINSIC SYSTEM

Figure 2. Left, Schematic representation of the interactions among platelet membrane receptors (glycoproteins Ia, Ib and IIblIIIa). adhesive macromolecules and the disrupted vessel wall. Numbers indicate the different pathways of platelet activation, dependent on I) collagen, 2) thrombin, 3) adenosine diphosphate (ADP) and serotonin, and 4) thromboxane A? (TxA,). Right The intrinsic and extrinsic systems of the coagulation cascade. Note the interaction between clotting factors and the platelet membrane. Ca = calcium; VWF = von Willebrand factor.

2.Thrombin

a-chain-

complex

Prothrombin -

muscle cells; it also attracts neutrophils and is a vasocon-

strictor (8,9). Platelet factor 4 (antiheparin factor) attracts neutrophiles and monocytes, perhaps serving as a stimulus to leukocyte accumulation in areas of endothelial injury (IO). The first pathway. How does the overall process of platelet aggregation take place? Through the action of several extrinsic activators such as collagen and thrombin (when there is vascular damage) and epinephrine, platelets change their shape from discs to spiny spheres. Calcium is then released from the dense tubular system into the cytoplasm by the action of phospholipase on platelet membrane phosphatidylinositol. This, in turn, is associated with the activation of the actin-myosin system, which results in platelet contraction with the release of adenosine diphosphate, serotonin and thromboxane AZ. It appears that collagen and thrombin not only contribute to platelet aggregation indirectly (through the release of the above compounds), but also have a direct effect on platelets, possibly through a platelet-activating factor (Fig. 3). For the purpose of this discussion, these reactions, which are dependent on collagen and thrombin, constitute the first pathway of platelet activation, leading to the exposure of platelet membrane receptors. The second prrthway. This pathway is mediated by sero-

Table 1. Content of Platelet Granules Dense granules Adenosine Alpha

diphosphate.

serotonin,

calcium.

phosphate

granules

Proteins factor Proteins

not present

in plasma:

present

fibronectin,

in plasma:

albumin,

fibrinogen,

thrombospondin,

Lysosomes Acid

hydrolases,

Peroxisomes Catalase

platelet-derived

growth

factor.

4, beta-thromboglobulin

cathepsin

D,E

von Willebrand platelet

factor

factor, 5

platelet

mcrnbronr

1 CO

I

Ll

Fibrinogen

Thromkn -

tonin and adenosine diphosphate, which are released from the platelet-dense granules after contraction. Adenosine diphosphate is a potent inducer of platelet aggregation in the presence of calcium and fibrinogen. It stimulates neighboring platelets to expose their binding sites to fibrinogen and von Willebrand factor (7), thus promoting aggregation. The high shear stress found in stenotic areas and at branching points within the arterial tree facilitates the deposition of platelets and the development and growth of thrombus (11). Furthermore, the turbulence present in these areas promotes red cell lysis, with the subsequent release of adenosine diphosphate, which in turn activates platelets and promotes their aggregation. 7’hc> third puthway. This pathway is mediated by arachidonic acid, which is released from the platelet membrane by the action of phospholipase A2 on phosphatidylcholine. Cyclooxygenase converts arachidonic acid into the proaggregating prostaglandin endoperoxide intermediates (prostaglandins G, and H,); thromboxane A2 is formed by the action of thromboxane synthetase, particularly on prostaglandin HZ. Thromboxane A2 is both a potent plateletaggregating substance and a vasoconstrictor. It stimulates platelet aggregation by promoting the mobilization of intracellular calcium and causing a conformational change in the glycoprotein IIb-IIIa complex, which results in the exposure of previously occult fibrinogen and von Willebrand factor binding sites (12,13). In summrr~. collagen thnt becomes exposed after vessel injury, thromhin generated by activution of the coagulation system and products of platelet secretion such as adenosine

diphosphate and thromboxane A2 can enhance the thrombotic process by stimulating adjacent platelets and facilitating the exposure of their membrane receptors to fibrinogen and von Willebrand factor. These reactions, in turn, promote further platelet aggregation and thrombus growth. Prostcrcyclin. In contrast, vascular tissue synthesizes

816

STEIN ET AL. PLATELET INHIBITOR AGENTS

TICLOPlOlNE?+--------.

A’.

JACC Vol. 14, No. 4 October 1989:813-36

r

h

~---____-_____-__._~~P~~,N~ i;;;7r_________“,R”O,N* “ANTICOAGULANTS+

Figure 3. Mechanismsof platelet activation and presumed sites of action of various platelet inhibitoragents. Platelet agonistslead to the mobilizationof calcium(Ca”), whichfunctionsas a mediatorof platelet activation throughmetabolicpathwaysdependenton adenosine diphosphate(ADP), thromboxane A, (TXA,), thrombin and collagen.Cyclicadenosinemonophosphate(CAMP)inhibitscalcium mobilizationfrom the dense tubularsystem. Note that thrombinand collagenmay independentlyactivate plateletsby meansof plateletactivatingfactor. Asterisk(*) indicates a platelet inhibitor. Dashed line indicates a presumed site of drug action. ATP = adenosine triphosphate;EPA = eicosapentaenoicacid; PGE, = prostaglandin E,; PGH, = prostaglandinH,; PGI, = prostaglandinI,.

prostacyclin (prostaglandin I,) from arachidonic acid (14) or platelet-derived prostaglandin GZ. Prostacyclin acts as a potent inhibitor of platelet aggregation by stimulating adenyl cyclase, which leads to an increase in cyclic adenosine monophosphate levels and a reduction in calcium mobilization from intracellular storage sites (15). Prostaglandins, cyclic adenosine monophosphate and intracellular calcium control platelet activity by interacting in a number of complex ways. Cyclic adenosine monophosphate inhibits both platelet secretion and aggregation, and its concentration depends on the activity of two enzymes (adenyl cyclase and phosphodiesterase). Whereas prostacyclin inhibits platelet aggregation by stimulating adenyl cyclase, thromboxane A, has the opposite biologic effect. Leukotrienes. The other metabolic pathway of arachidonic acid is mediated by the enzyme lipoxygenase, which results in the production of leukotrienes. These compounds have been associated with a number of pathophysiologic reactions including immune-mediated reactions, chemotaxis for neutrophils, constrictor actions on various smooth mus-

cle beds (particularly the coronary vessels) and platelet aggregation. Our understanding of the effects of leukotrienes on the cardiovascular system is evolving. Activation of the clotting system. In addition to adhering to the injured vascular wall and forming aggregates, activated platelets markedly accelerate the generation of thrombin (16). Perhaps by rearranging their surface lipoproteins during contraction, activated platelets promote the interaction of clotting factors (16). It is on the platelet surface where the interactions between factors IX and VIII and factors X and V occur (Fig. 2). Furthermore, the binding of thrombin and other activated clotting factors to platelets may protect them from inhibition (17). The intrinsic coagulation pathway is initiated when blood comes in contact with the deendothelialized vascular surface. In the extrinsic pathway, a lipoprotein called tissue

factor or tissue thromboplastin is released into the plasma and initiates the coagulation process. Aside from the intrinsic and extrinsic activation, both the negatively charged phospholipids on the platelet surface and calcium are essential for maximal activation of factor X. Once factor X is activated, prothrombin is converted to thrombin, which cleaves fibrinogen to fibrin and activates factor XIII. This factor catalyzes the crosslinking reaction of fibrin. Polymerized fibrin, in turn, stabilizes the platelet mass and allows the arterial thrombus to withstand the high intravascular pressure and force of blood flow. In addition, it should be emphasized that thrombin itself is a powerful platelet activator. Endogenous inhibitors of thrombus formation. During platelet activation and fibrin formation, endogenous mecha-

JACC Vol. 14, No. 4 October 1989:813-36

PLATELET

nisms tend to limit thrombus formation (Fig. 1). The most important of these are prostacyclin (discussed earlier), antithrombin III, protein C and the fibrinolytic system. Prostacyclin inhibits platelet aggregation by increasing platelet cyclic adenosine monophosphate and reducing the mobilization of calcium from its storage sites (15). Antithrombin III is an important endogenous anticoagulant that inhibits thrombin and activated factors IX, X, XI and XII (18). Its inhibitory action is markedly increased by heparin. Plasminogen activators and inhibitors. Protein C is activated by the association of thrombin with thrombomodulin. In addition to being a potent anticoagulant, protein C initiates fibrinolysis by activating plasminogen and neutralizing a circulating inhibitor of tissue plasminogen activator (19). Once activated, plasminogen is converted to plasmin, which hydrolizes fibrin into soluble fragments and degrades fibrinogen, prothrombin and factors VIII and V (20). The proteolytic activity of plasmin remains localized to the fibrin surface; as fibrin degradation proceeds to completion, plasmin is rapidly inactivated by alpha-2 plasmin inhibitor. A specific plasminogen activator inhibitor (type I) has been identified in human platelets (21) and in the extracellular matrix of cultured endothelial cells (22). Recent findings underscore the importance of the fibrinolytic system in maintaining normal hemostasis and suggest that the balance between plasminogen activators and inhibitors may be important in both arterial and venous thrombotic disorders.

Pharmacology of Platelet Inhibitor Drugs There has been a continuous interest in the mechanism of action of drugs that interfere with platelet function in atherosclerosis, thrombosis and embolism. Platelet inhibitors may exert their effects through several mechanisms including direct inhibition of the arachidonic acid pathway, increase in platelet cyclic adenosine monophosphate levels and inhibition of thrombin formation and action (Fig. 3). Inhibitors

of the At-achidonic

Acid Pathway

Inhibitorsof plateletcyclooxygenase(aspirin). Aspirin and other nonsteroidal anti-inflammatory drugs acetylate the platelet enzyme cyclooxygenase and, thus, inhibit the formation of thromboxane A,. Aspirin only partially inhibits platelet aggregation induced by adenosine diphosphate, collagen or thrombin (at low concentrations). The adherence of the initial layer of platelets to the subendothelium and the release of granule contents are not inhibited by aspirin (23). Consequently, the effects of platelet-derived growth factor and other mitogens on smooth muscle cell proliferation may still occur in the presence of cyclooxygenase inhibitors (24). In contrast, these drugs inhibit platelet aggregate formation on the layer of adherent platelets, presumably by blocking thromboxane A, synthesis.

STEIN ET AL. INHIBITOR AGENTS

817

The acetylation of cyclooxygenase in platelets exposed to (25) and, thus, the effects of the drug is permanent persist for the life of the platelets. The long-term administration of 1 mg/kg per day of aspirin effectively inhibits platelet cyclooxygenase and thromboxane A, formation. In contrast, aspirin inhibition of vascular endothelial cyclooxygenase is not irreversible because these cells are capable of synthesizing new enzyme, though they may require several hours to do so. Although earlier studies suggested that platelet cyclooxygenase was more sensitive to the inhibitory effects of low dose aspirin than was vascular wall cyclooxygenase, more recent experimental data (26) challenge this concept. aspirin

The antithrombotic a dose

of 160

effect of aspirin

to 325 mglday

effects associated

and,

can be achieved

therefore,

with

the toxic side

with higher doses can be avoided

(27-29).

Side effects are dose related and predominantly involve the gastrointestinal tract (30). Although higher doses of aspirin (>I,000 mgiday) are effective in terms of antithrombotic activity, they are associated with substantial gastrointestinal toxicity (30,31). For all of these reasons, an aspirin dose of 160 to 325 mgiday for the prevention of thromboembolic disease is currently recommended. Aspirin rarely causes significant generalized bleeding unless it is combined with anticoagulant therapy. When the risk of thrombosis is high, as in unstable angina or during coronary intervention, the combination of low dose aspirin (~325 mglday) and an anticoagulant is being tested. However, higher doses of aspirin can be associated with significant gastrointestinal bleeding. Although ibly inhibit

nonsteroidal cyclooxygenase,

anti-inflammatory

drugs

revers-

the antithrombotic activity of these compounds has not been properly tested in large randomized trials and, therefore, their use cannot be recommended (32). Furthermore, one of the nonsteroidal antiinflammatory agents, indomethacin, has been found to increase coronary vascular resistance and exacerbate ischemic attacks in patients with coronary disease (33). Drugsthat alter plateletmembranephospholipids(omega-3 fatty acids). Both eicosapentaenoic acid and docosahexaenoic acid are present in high concentration in most salt water fish, and may account for the lower incidence of coronary heart disease in Greenland Eskimos and populations that consume large amounts of fish (34,35). Eicosapentaenoic acid competes with arachidonic acid for platelet cyclooxygenase. This leads to the formation of two endoperoxidases (prostaglandins G, and H,) and thromboxane A,, which have minimal biologic activity (36). Furthermore, eicosapentaenoic acid not only does not inhibit endothelial prostacyclin production, but also stimulates the formation of prostaglandin I,. which has antiplatelet activity (36). The net result is a shift in the hemostatic balance toward an antiaggregative and vasodilative state. Docosahexaenoic acid also has platelet inhibitory effects and undergoes retroconversion

818

STEIN ET AL. PLATELET INHIBITOR AGENTS

to eicosapentaenoic acid (37). Although fish consumption may decrease the incidence of coronary heart disease, fish oils are associated with some potentially adverse events such as increased bleeding diathesis and reduced inflammatory and immune responses (37). Before fish oils are recommended for the prevention of atherosclerosis, properly designed and controlled human trials are necessary (36). The role of fish oils in the prevention of restenosis after coronary angioplasty is reviewed later. Inhibitors of thromboxane synthetase. Imidazole analogue thromboxane synthetase inhibitors have been developed with the expectation of not only suppressing thromboxane A, biosynthesis, but sparing or even enhancing the formation of prostacyclin by the vascular endothelium (38). The rationale behind this hypothesis was that, in the presence of a thromboxane synthetase inhibitor, platelet-derived prostaglandin G, would be transferred to the endothelial cells and used in the production of prostacyclin. Although thromboxane synthetase inhibitors have shown some benefits in experimental models (39), their effects in clinical trials (40,41) in patients with coronary artery disease have been controversial. This may be a result of two factors: 1) thromboxane A, may not be completely suppressed by the available compounds, and 2) the prostaglandin endoperoxide intermediates that result from thromboxane synthetase inhibition have themselves significant proaggregating effects. Blockers of thromboxane and prostaglandinendoperoxide receptors. A promising approach to the inhibition of the proaggregating and vasoconstrictive effects of thromboxane A, is the pharmacologic blockade of the receptors for both thromboxane A, and the prostaglandin endoperoxidases (42). However, it remains to be demonstrated that such agents will offer an advantage over aspirin in suppressing thromboxane AZ-dependent platelet function. The combination of a thromboxane synthetase inhibitor (which potentiates prostacyclin synthesis) and a thromboxane A,prostaglandin H, receptor blocker (which prevents the proaggregative effect of these compounds) may offer a unique approach to platelet inhibition (43) but requires further testing. Drugs That Increase Platelet Cyclic Adenosine Monophosphate Levels Dipyridamole. Dipyridamole may increase platelet cyclic adenosine monophosphate by three mechanisms: 1) It blocks its breakdown by inhibiting phosphodiesterase; 2) it activates adenylate cyclase by a prostacyclin-mediated effect on the platelet membrane (44); and 3) it increases the levels of plasma adenosine by inhibiting its uptake by vascular endothelium and erythrocytes (45,46). Adenosine, in turn, enhances platelet adenylate cyclase activity. In addition, the vasodilative effects of dipyridamole also appear to be related to the elevation in plasma adenosine levels. Although there

JACC Vol. 14, No. 4 October 1989:813-36

are in vitro data to support dipyridamole’s mechanisms of action on the platelet, there is no firm clinical evidence that such mechanisms contribute to a significant antithrombotic effect in humans (46). Dipyridamole vs. aspirin. In contrast to aspirin, the antithrombotic effects of dipyridamole are more evident on prosthetic materials (artificial heart valves [47,48] and arteriovenous cannulas [49]) than on biologic surfaces. Although one study (50) showed that aspirin potentiates the efficacy of dipyridamole in experimental thromboembolism on prosthetic surfaces, other studies (46) have shown conflicting results with regard to the pharmacologic interaction between these two agents. Furthermore, aspirin alone was as effective as the combination of aspirin and dipyridamole in recent antithrombotic trials (51-55) in myocardial infarction, saphenous vein graft disease and stroke. On the basis of these findings, there is little evidence to support the use of dipyridamole as an antithrombotic agent except in combination with warfarin in high risk patients with a mechanical prosthesis (56-60) and possibly in the preoperative period in patients with coronary artery bypass surgery (61,62). The main side effects of dipyridamole are headache, epigastric discomfort and nausea, which occur in >lO% of patients but subsequently subside. The agent is not associated with gastritis or gastroduodenal ulcers and does not increase the bleeding tendency, even when combined with an anticoagulant. ProstaglandinsE, and I,. These prostaglandins are powerful systemic vasodilators and inhibitors of platelet aggregation by virtue of their ability to increase platelet cyclic adenosine monophosphate. Intravenous infusions of prostaglandin E, are commonly used in neonates with congenital heart disease, who are dependent on the persistence of a patent ductus arteriosus until surgical correction is done. These agents have also been used to improve myocardial function in patients with acute myocardial infarction and to treat peripheral vascular disease (63). Prostacyclin. Prostacyclin is a potent, naturally occurring platelet inhibitor. Its clinical use has been limited by its instability at neutral pH and its propensity to cause significant systemic hypotension at the doses required for platelet inhibition. Its duration of action is very short, and the pharmacologic effects disappear in 30 min. Infusion of prostacyclin strongly limits platelet interaction with artificial surfaces and preserves platelet number and function during cardiopulmonary bypass (64,65). The effects of prostacyclin in patients with ischemic heart disease and peripheral vascular insufficiency are controversial (63). Emerging data, however, suggest that these prostanoids may improve the results of intracoronary thrombolysis in acute myocardial infarction (66,67). Further research in this area is needed. Prostacyclin analogues. Iloprost, a newly synthetized prostacyclin analogue, is chemically stable at neutral pH. In

JACC Vol. 14. No. 4 October 1989:813-36

an in vitro comparison with equimolar concentrations of prostaglandins I? and E,, iloprost was found to be more potent in increasing the levels of platelet cyclic adenosine monophosphate and inhibiting platelet aggregation by various agonists, particularly thrombin (68). Another prostacyclin analogue, ciprostene, was found to reduce the rate of ischemic events in patients after coronary angioplasty, and was associated with a beneficial trend toward a lower rate of restenosis (69). Therefore, chemically stable analogues of prostacyclin may be effective for temporary control of platelet activity in the management of thromboembolic disorders. These compounds are currently undergoing clinical testing.

Thromhin Inhibitors By inhibiting thrombin formation with heparin or oral anticoagulant agents, the effects of thrombin on platelets and fibrinogen activation can be partially prevented. Heparin. Aside from the antithrombotic effects of heparin, mainly by enhancing antithrombin III activity, the effects of this agent on platelet reactions are complex and contradictory (70), partly because of the variability among different commercially available preparations. There is evidence that suggests that fractions of high molecular weight (approximately 20,000 daltons) are more reactive with platelets (promoting their aggregation) than are fractions of low molecular weight (approximately 7,000 daltons). Therefore, antithrombotic therapy may be enhanced by selecting heparin fractions of low molecular weight and high antithrombin III activity. In addition to its antithrombotic effects. high dose heparin has inhibitory effects on smooth muscle cell proliferation that have been demonstrated experimentally (71,72): these effects opens interesting therapeutic opportunities, particularly with respect to restenosis after coronary angioplasty. Peptide blockers of thrombin. An alternative strategy involves the synthesis of peptides that specifically block thrombin-mediated platelet activation (73). A number of these agents have been studied in vitro and in experimental animals; however, no clinical experience is yet available. Another potent selective thrombin inhibitor, hirudin, initially isolated from the salivary secretions of the medicinal leech, was recently synthesized by deoxyribonucleic acid recombinant technology. Hirudin prevents the activation of clotting factors V. VIII and XIII; in addition, by being a powerful thrombin inhibitor, it blocks the metabolic pathway of platelet activation dependent on thrombin. Hirudin was recently shown (74) to prevent thrombosis in an animal model of carotid angioplasty, and was found to have a more potent antithrombotic effect than heparin. Because these agents may effectively inhibit platelet activation by blocking thrombin, their potential for clinical use is enormous. Intensive research in this area is currently underway.

PLATELET

STEIN ET AL. INHIBITOR AGENTS

819

Other Platelet Inhibitors Ticlopidine. Ticlopidine is chemically unrelated to other antiplatelet drugs; its mechanism of action is not completely understood. It may act on the platelet membrane to alter its reactivity. perhaps by blocking the interaction of von Willebrand factor and fibrinogen with platelets (75). It inhibits platelet aggregation induced by adenosine diphosphate and most other agonists, prolongs bleeding time and normalizes shortened platelet survival (76). Optimal efficacy is reached only after 3 days after its administration, and its effects last for several days after administration of the drug has been stopped. Clinicml evaluation oj’this drug is now underway. Preliminary evidence from an Italian multicenter trial (77) suggests that it is effective in patients with unstable angina for the prevention of myocardial infarction and cardiovascular death. Another recent study (78) showed a reduction in the incidence of acute occlusion and thrombosis after coronary angioplasty in patients treated with ticlopidine. In addition, this agent was found to be effective in reducing vein graft closure in patients after aortocoronary bypass surgery (79). Recently published data (80,81) suggest that ticlopidine reduces cardiovascular morbidity and mortality in patients with stroke, and appears more effective than aspirin in patients with transient ischemic attacks. However, ticlopidine is associated with side effects including rash and neutropenia. Sulfinpyrazone. Sulfinpyrazone is structurally related to phenylbutazone but has minimal anti-inflammatory activity. In contrast to aspirin, sulfinpyrazone is a competitive inhibitor of platelet cyclooxygenase, but the exact mechanism of its antithrombotic activity is not well understood (50). It inhibits the formation of thrombus on subendothelium and protects the endothelium from chemical injury in vitro and possibly in vivo. In addition, sulfinpyrazone produces a dose-dependent inhibition of experimental thromboembolism in artificial cannulas (50) reduces the rate of thrombotic events in patients with arteriovenous cannulas (82) and normalizes platelet survival in patients with artificial heart valves (83). Overall, beneficial effects have been more consistent on prosthetic than on biologic surfaces. Thus, despite a beneficial trend in decreasing vascular events after myocardial infarction (84) and in reducing the occlusion rates in saphenous vein coronary artery grafts (55,85), sulfinpyrazone was found to have no additional benefit in unstable angina (31) and stroke (86). Side effects of sulfinpyrazone include increased sensitivity to warfarin, hypoglycemia when combined with sulfonylureas, exacerbation of peptic ulcer and precipitation of uric acid stones. Dextran. Dextran of a molecular weight of 65,000 to 80,000 daltons prolongs the bleeding time after intravenous infusion of ~1 liter. Its mechanism of action is unclear. It may involve some alteration on platelet membrane function

820

JACC Vol. 14, No. 4 October 1989:813-36

STEIN ET AL. PLATELET INHIBITOR AGENTS

(87) or interference with the factor VIII-von Willebrand factor complex (88). Although some experimental studies (89) have shown an antithrombotic effect of dextran, no effect was found in a randomized trial (90) in patients undergoing coronary angioplasty. Furthermore, dextran has been associated with a low but disturbing incidence (0.6%) of anaphylactoid reactions (91). Data supporting the role of dextran as an antithrombotic agent on foreign materials (that is, arterial stents and vascular grafts) are emerging. Future developments. Currently available drugs do not interfere with all the platelet metabolic pathways that lead to their activation; therefore, these agents are unable to entirely prevent thrombus formation. As previously discussed, the exposure of receptors in the platelet membrane that bind fibrinogen and von Willebrand factor seems to play a pivotal role in platelet aggregation (Fig. 2). Therefore, short-term total inhibition of platelet aggregation may depend on the use of agents such as monoclonal antibodies, which block either the fibrinogen receptors on the platelet membrane (92,93) or the adhesive macromolecules such as von Willebrand factor (94). Similarly, agents that inhibit platelet membrane receptors responsible for platelet adhesion may be useful for short-term therapy. However, long-term therapy may be hazardous because of increased bleeding tendency. Finally, agents that block the biochemical steps responsible for platelet contraction and granular release may play an important role in the inhibition of the processes of platelet secretion and aggregation and should be investigated.

Role of Platelet Inhibitor Agents in Cardiovascular Disease With a better understanding of the pathogenetic mechanisms involved in many cardiovascular disorders, the role of platelets in thrombosis and thromboembolism has been established, and a more extensive role for antithrombotic therauv . - has emerged. We will review the available data on antithrombotic therapy in different cardiovascular syndromes, with particular emphasis on the indications for platelet inhibitors, based on the results of clinical trials. Coronary Atherosclerotic Disease The natural history of coronary atherosclerotic disease includes a long initial asymptomatic period that lasts three to four decades and that may be characterized by benign, raised, nonobstructive fatty streaks in the coronary vessels. In the presence of a genetic predisposition and certain coronary risk factors, these raised plaques grow and either remain silent or produce clinical symptoms of angina pectoris. The acute coronary syndromes, namely, unstable angina, myocardial infarction and ischemic sudden death, may occur when growing plaques undergo a rapid morphologic change after they rupture, with significant occlusive or near

Table 2. Proposed Model of Sequential Events in Coronary Atherosclerotic Disease Early lesions (asymptomatic stage) Hemodynamic factors: endothelial damage Platelet and monocyte deposition Smooth muscle cell migration and proliferation Connective tissue synthesis Lipid transformation and deposition Growing lesions (asymptomatic or stable angina stage) Slow process Chronic endothelial injury Platelet and monocyte interaction with vessel wall Smooth muscle cell proliferation, collagen synthesis, lipid accumulation Rapid process Intermittent fissuring of coronary plaques Nonocclusive thrombus formation* Fibrotic organization of thrombus Plaque rupture (acute coronary syndromes) Unstable angina Plaque rupture with transient thrombosis* Vasospasm Increased myocardial oxygen demand Myocardial infarction Plaque rupture with thrombotic occlussion* Vasospasm Spontaneous recanalization and rethrombosis* *Events that may be prevented or diminished by use of antithrombotic therapy.

occlusive thrombus formation (Table 2). Finally, extensive coronary artery disease or myocardial infarction may lead to left ventricular dysfunction. The roles of platelets and platelet inhibitors in the asymptomatic phase of coronary atherosclerosis and in the phases of stable angina and acute ischemic syndromes will be reviewed. Asymptomatic

and Stable Angina Phases

Knowledge of the pathogenesis of atherosclerosis, although still incomplete, is rapidly evolving. The process is multifactorial in origin and involves the interaction of genetic factors, platelets, smooth muscle cells, endothelium, cholesterol and lipoproteins. Slow progressionof atherosclerosis. Platelet deposition in areas of subtle endothelial injury may constitute one of the initiating factors in the development of atheromatous plaque. Areas of increased turbulence such as branching points are particularly susceptible to endothelial injury. Through the interaction of von Willebrand factor, collagen, fibronectin and other proteins, platelets become firmly attached to gaps between endothelial cells or to injured vascular wall, and may release several mitogens including platelet-derived growth factor, epidermal growth factor and transforming growth factor beta. These factors stimulate the proliferation and migration of smooth muscle cells and fibroblasts from

JACC Vol. 14. No. 4 October 1989:813-36

the media to the intima of the vessel wall. Platelet interaction with injured endothelium may induce a rapid proliferative response, whereas other sources of growth factors including activated macrophages and endothelial cells may be responsible for stimulating smooth muscle cells at a slower rate and producing atherosclerosis even in the absence of endothelial disruption (95). In the experimental hyperlipidemic model of atherosclerosis (95), monocytes attach to the endothelium early after the induction of hypercholesterolemia. These monocytes then localize subendothehally, accumulate lipid and become foam cells, which eventually constitute fatty streaks. After several months. the endothelium that covers the fatty streaks retracts and allows the attachment of platelets to areas of endothelial desquamation or to the subendothelium (95). All principal cells involved in the atherosclerotic process-endothelium, platelets, monocytes and smooth muscle cells-are capable of releasing chemotactic and mitogenic factors. In hyperlipidemia, interaction of monocytes with the vessel wall and monocyte-dependent growth factor or factors may be more important than platelet-dependent factors. lf plutelet adherence to the vessel wall plays a role in utherogenesis, then inhibition of platelet adhesion may be beneficial in preventing atherosclerosis. Unfortunately, no drug with this property is currently available. If platelet adhesion were to be completely prevented by a pharmacologic agent, as occurs in pigs with an absence or alteration of von Willebrand factor (96), the risk of bleeding would prohibit its long-term use. In contrast, such an agent may prove beneficial when short-term inhibition of platelet adhesion is desired (such as during coronary angioplasty or after coronary thrombolysis). Primary prevention. Results from a double-blind, placebocontrolled trial (97) of >22,000 male physicians in the United States assigned to receive aspirin (325 mg every other day) for 5 years revealed a 44% reduction in the incidence of myocardial infarction from approximately 0.4% to 0.2% per year (p < 0.00001). Before advising the widespread use of aspirin in apparently healthy people, three issues need to be considered. First, there was a slight increase in the incidence of hemorrhagic stroke in the aspirin-treated group. Second, in a randomized British primary prevention trial (98) that involved >5,000 male physicians, the use of aspirin (500 mg/day) did not reduce the rate of myocardial infarction, but did increase the incidence of disabling stroke. Third, the long-term effects of aspirin blockade of the prostaglandin system in various tissues. particularly the central nervous system, are unknown. Increase in hemorrhagic stroke. Even though these studies were done in healthy volunteers and, admittedly, their conclusions should be applied only to “healthy individuals,” the increased incidence of hemorrhagic stroke is disconcerting. Therefore, we recommend aspirin for primary preven-

PLATELET

STEIN ET AL. INHIBITOR AGENTS

821

tion only to individuals at high risk for coronary artery disease, in whom the benefits of therapy outweigh its risks. Further analysis (98a) of the United States Physicians’ Health Study (97) suggests that aspirin exerts a greater impact on patients at higher risk for coronary events, namely those with cardiovascular risk factors or evidence of cerebral or peripheral vascular disease. Progression of atherosclerosis. Rupture of small atherosclerotic plaques, with subsequent mural thrombosis and fibrotic organization of thrombus, may contribute to the progression of coronary atherosclerosis. This concept is based on the pathologic finding of old, organized coronary thrombi difficult to distinguish from atherosclerotic changes seen in the arterial wail (99). A more recent study (100) demonstrated the presence of fibrinogen, fibrin and their degradation products in areas of advanced atherosclerotic plaques. On the basis of these observations, recurrent episodes of plaque disruption and thrombosis may lead not necessarily to acute ischemic syndromes, but to progressive narrowing of the coronary arteries. Although it is as yet unknown how prevalent this process is, its clinical significance is potentially enormous because thrombotic episodes may be prevented by platelet inhibitors or anticoagulant agents. In this context, a 5 year trial of platelet inhibitor therapy in the angiographic progression of coronary disease in patients with stable angina was recently completed at the Mayo Clinic. Preliminary evidence suggests that platelet inhibitors reduce the incidence of myocardial infarction and new lesion formation (lOOa). Acute

Coronury

Syndromes

Angiographic (101,102), angioscopic (103) and pathologic (104.105) studies have demonstrated the presence of complex ulcerated plaques with or without thrombus formation in a large proportion of patients with unstable angina, myocardial infarction or ischemic sudden death. The causes of plaque rupture are unknown, but may be related to the physicochemical properties of the plaque (fragility of the fibrous cap, infiltration by foam cells, abnormal elastin), hemodynamic factors (wall shear stress, changes in vasotonicity and blood pressure) and continuous arterial bending and twisting with each cardiac cycle. Plaque rupture exposes collagen fibrils and tissue thromboplastin, promoting the development of thrombus. The degree, suddenness and duration of the obstruction and size of the involved vessel probably determine the nature of the clinical event. Unstable angina (Table 3). Plaque disruption in areas of mild coronary stenosis may lead to an acute change in plaque morphology and a reduction in coronary blood flow, resulting in progressive ischemic symptoms. Transient episodes of thrombotic vessel occlusion at the site of injury may occur, resulting in rest angina (103). Additionally, blood supply may be further compromised by intermittent vasoconstriction

822

JACC Vol. 14, No. 4 October 1989:813-36

STEIN ET AL. PLATELET INHIBITOR AGENTS

Table 3. Reported Results of Antithrombotic Therapy in Unstable Angina Reduction in Event Rate (%)

No. of Patients

Trial (reference)

Follow-up

214 1,216 555

Telford and Wilson (108) VACS (27) Cairns et al. (31)

Drug Heparin Aspirin Aspirin Sulfinpyrazone Aspirin Heparin Ticlopidine

7 days 12 weeks 18 months

Theroux et al (107)

479

6 days

STAI (77)

652

6 months

Mortality 51 718 9 57

Cardiac Death t MI 80* 51t 51P (-6) 728 89t 531

*p < 0.05; tp < 0.001;Sp < 0.005; §p < 0.01. MI = myocardial infarction; STAI = Study ofTiclopidine in Unstable Angina; VACS = Veterans Administration Cooperative Study.

related to the release of vasoactive substances from platelets or to a deficiency of endothelium-derived relaxing factor in areas of atherosclerosis (106). Alternatively, transient increases in myocardial oxygen demand may explain some of the episodes of unstable angina. Aspirin therapy. There have been three large, randomized, placebo-controlled, double-blind studies of aspirin in unstable angina. In the Veterans Administration Cooperative Study (27), 1,266 men with unstable angina were randomized to buffered aspirin (324 mg/day) or placebo for 12 weeks. During the treatment period, the incidence of death and acute myocardial infarction was reduced from 10.1% to 5.0% in the treated group (p = 0.0005). More importantly, the overall benefits of aspirin were maintained in the 1 year follow-up period. No increase in gastrointestinal side effects was seen in the aspirin-treated group. In the Canadian Multicenter Trial (3 I), 555 patients (73% men) with unstable angina were randomized to receive aspirin (1,300 mg/day), sulfinpyrazone (800 mg/day), the combination of both, or placebo. After 2 years, the incidence of death and myocardial infarction was reduced in the aspirin-treated groups from 17% to 8.6%, a risk reduction of 51% (p = 0.008) (Fig. 4). Sulfinpyrazone conferred no benefit and did not interact with aspirin. Gastrointestinal toxicity was more frequently

Figure 4. Efficacy of aspirin versus no aspirin in reducing cardiac death or nonfatal myocardial infarction in patients with unstable angina. Continuous line indicates aspirin-treated patients; dotted line indicates patients who did not receive aspirin. Reproduced with permission from N Engl J Med (31). I- 20

I

I

I

I

I

z z

I5

-

z 5 fz E c 2

-------/_

IO-

$L

% 8

0

I

3mo

I

6mo

I

I

I

1 Yr

16 mo

2 Yr

TIME

seen in the aspirin-treated groups, probably related to the high dose used. In the recently published Montreal Heart Institute Study (107), 479 patients with unstable angina were randomized to

aspirin (325 mg twice daily), intravenous heparin, the combination of both, or placebo. The study was ended after a mean of 6 days when a final therapeutic decision for the individual patient was made. Aspirin significantly reduced rate of myocardial infarction by 72% compared with placebo. Further support for the use of antiplatelet agents in unstable angina comes from the recently completed Italian Study of Ticlopidine in Unstable Angina (S.T.A.I.) (77). Preliminary evidence from this study showed that ticlopidine at a dose of 250 mg twice daily for 6 months reduced the incidence of mortality and myocardial infarction by >50%. Anticoagulant therapy. Evidence of a beneficial effect of heparin in unstable angina was suggested by Telford and Wilson (108), who demonstrated an 80% reduction in the incidence of myocardial infarction in patients with unstable angina treated with heparin for 7 days. Deficiencies in patient recruitment, however, left the conclusions of this study less convincing. The strongest support for immediate anticoagulation in unstable angina comes from the Montreal Heart Institute Study (107). Heparin decreased the rate of infarction by 89% and the incidence of refractory angina by 50%. Although no statistically significant difference among aspirin, heparin or their combination was found, there was a trend favoring heparin over aspirin. The combination was associated with a slight increase in bleeding complications. This study confirms the concept that an aggressive antithrombotic approach to patients with unstable angina is beneficial. A multicenter randomized trial of anticoagulants plus low dose aspirin in unstable angina is currently underway. Non-Q wave infarction. The angiographic configuration of the responsible lesion in non-Q wave infarction is similar to that seen in unstable angina (109), which suggests that plaque disruption is common in both syndromes. The presence of ST segment elevation on the electrocardiogram

JACC Vol. 14, No. 4 October 1989:813-36

(ECG) (1 lo), early peak in plasma creatine kinase (1 IO,I1 1) and high angiographic patency rates of the infarct-related artery (110-l 12) suggest that complete coronary occlusion followed by early reperfusion is important in the pathogenesis of non-Q wave infarction. Reperfusion may occur as a result of spontaneous thrombolysis or resolution of vasospasm. or both. Furthermore, contraction band necrosis, which is the hallmark of reperfusion, is more often found in patients dying of non-Q wave versus Q wave infarction (113). In contrast, when complete coronary occlusion is persistent, the presence of adequate collateral flow may limit the extent of myocardial necrosis and prevent the development of a Q wave infarction (112). Given the high incidence of reinfarction and vascular death in these patients, not unlike those with unstable angina, aggressive antithrombotic therapy may be beneficial. This hypothesis requires clinical testing. Q wave infarction. In Q wave infarction, atherosclerotic plaque rupture leads to fixed and persistent occlusive thrombus formation (104). Quantitative angiographic studies ( 114) have shown that the coronary lesion responsible for the infarction may be only mild to moderately stenotic. This suggests that plaque rupture with thrombus formation, rather than the severity of the underlying stenosis (114-l 16), may be the primary determinant of acute occlusion. Myocardial infarction may also be favored by alterations inhemostasis, such as increased activation of the coagulation system, increased platelet aggregability, elevated fibrinogen, increased factor VII activity or deficient fibrinolytic mechanisms (117,118). Platelet inhibitor therapy. The strongest evidence supporting the use of platelet inhibitors in the acute stage of myocardial infarction comes from the recently published Second International Study of Infarct Survival (ISIS-2) (29). In this study, >17,000 patients with suspected acute myocardial infarction were randomized to aspirin (160 mg/day), intravenous streptokinase, both or placebo. At 5 weeks, the vascular mortality rate was significantly reduced by aspirin alone (by 23%), streptokinase alone (by 25%) and the combination of both (by 42%). Because a certain number of patients with acute infarction undergo spontaneous or chemically induced vessel recanalization, aspirin probably owes its beneficial effects to a reduction in early reinfarction. Indeed, aspirin decreased the rate of nonfatal reinfarction by 50% in this study (29). It should be noted that because admission into this trial did not require ECG confirmation of acute infarction, some patients probably had unstable angina, a situation for which aspirin has clearly proved to be beneficial (27,31,107). Anticoagulant therapy. Although the purpose of this review is to analyze the value of platelet inhibitor therapy in cardiovascular disease, it is important to mention briefly the results obtained with the use of anticoagulants. The role of anticoagulants in patients with acute infarction for the pre-

PLATELET

STEIN ET AL. INHIBITOR AGENTS

823

vention of coronary rethrombosis, infarct extension and death has not been settled. Of the large number of studies conducted, only three randomized trials (I 19-121) have been sufficiently large to be able to detect a significant effect of therapy. Although all three studies showed a beneficial trend toward reduced incidence of death and reinfarction, only the Bronx Municipal Hospital trial (120) found a significant reduction (30%) in the case fatality rate. In addition, anticoagulant therapy has been clearly shown to reduce pulmonary and systemic embolism after myocardial infarction (119-121) and the incidence of left ventricular mural thrombosis in cases of acute anterior infarction (122). Therefore, it appears that in patients with acute myocardial infarction, both aspirin and short-term anticoagulant therapy are associated with lower incidence of death and reinfarction (29,123).

Secondury InjkircTion

Prevention

After

Myocurdial

Antiplatelet therapy (Table 4). With respect to the use of antiplatelet agents for secondary prevention of vascular events, several large, randomized, placebo-controlled, double-blind trials (5 I ,84,124-130) in postmyocardial infarction patients have been conducted. In seven of these trials, aspirin (at a dose of 300 to 1,500 mgiday) was used alone or combined with dipyridamole. In the remaining two trials, sulfinpyrazone was used. Despite the large total number of patients studied (>17,000), no clear evidence of benefit from therapy was shown in any single study. Reduction in cardiac mortality rate varied from 5% to 42%, and in nonfatal reinfarction rate from 12% to 57% (Table 4). The largest single trial, the Aspirin Myocardial Infarction Study (128), showed no benefit from therapy, but unbalanced randomization introduced an inadvertent bias against aspirin. The rest of the trials disclosed a beneficial trend from therapy in terms of lower mortality rate and, in some cases, a significant reduction in coronary event rate (84,127,130). A pooled analysis of antiplatelet therapy in secondary prevention after myocardial infarction was recently published in the British Medical Journul (131). It suggests that, in survivors of myocardial infarction, platelet inhibitors significantly reduce the vascular mortality rate by 13%, nonfatal reinfarction rate by 3 1% and nonfatal stroke rate by 42% without any effect on the nonvascular mortality rate. Although no statistically significant differences among the antiplatelet agents used were found, current evidence does not justify the additional expense and increased frequency of administration of dipyridamole or sulfinpyrazone (46,13I). At present, the best studied, most convenient and least expensive antiplatelet drug appears to be aspirin at a dose no greater than 325 mg/day. Anticoagulant therapy. Numerous studies have assessed the usefulness of long-term anticoagulation in the secondary

824

STEIN ET AL. PLATELET INHIBITOR AGENTS

JACC Vol. 14, No. 4 October 1989:813-36

Table 4. RandomizedTrials of Platelet Inhibitorsfor Secondary Preventionof MyocardialInfarction Reduction in Event Rate With Therapy (%) Trial (reference)

No. of Patients

MRC-I (124) CDP (125) GARS (126) MRC-II (127) AMIS (128) PARIS-I (51)

1.239 1,529 626 1,682 4,524 2,206

ART (129) ARKS(84) PARIS-II (130)

1,558 727 3,128

Drug(mgday) Aspirin (300) Aspirin (972) Aspirin (1,500) Aspirin (900) Aspirin (1,000) Aspirin (972) Aspirin (972) t dipyridamole (225) Sulfmpyrazone (800) Sulfinpyrazone (800) Aspirin (990) t dipyridamole (225)

Total Mortality

Cardiac Mortality

Coronary Events

24 30 I8 17

NA 28 42 22

NA 22 37 2g* 5 24 25 NA 563: 24*

(- 10) 18 16 2gt 5 3

C-8) 21 24 24t 5 6

*p < 0.05; tLower total and cardiac mortality are due to a marked reduction in early sudden death. Sp < 0.01. AMIS = Aspirin Myocardial Infarction Study; ARIS = Anturane Reinfarction Italian Study; ART = Anturane Reinfarction Trial; CDP = Coronary Drug Project; CARS = German-Austrian Reinfarction Study; MRC-I = Medical Research Council (1974);MRC-II = Medical Research Council (1979);NA = Not available; PARIS-I = Persantine-Aspirin Reinfarction Study (1980);PARIS-II = Persantine-Aspirin Reinfarction Study (1986).

prevention of cardiovascular disease after myocardial infarction, but only four randomized controlled trials (126,132134)were large enough to be able to detect a significant effect from therapy. Three of these studies (126,132,133) randomized patients soon after infarction and followed their course for several years. Although no significant reduction in the mortality rate was seen in any of the trials, anticoagulant therapy reduced the reinfarction rate by 60% in the Medical Research Council Study (132). Utilizing a different design, the Sixty Plus Reinfarction Study (134) entered patients >60 years of age who had been maintained on anticoagulant therapy for a median of 6 years after infarction. Patients were randomized to continuation of anticoagulant therapy or to placebo substitute. At the end of 2 years, patients taking anticoagulants had a 26% lower death rate (p = 0.07) and an impressive 55% reduction in the incidence of reinfarction (p = 0.0005). The recently completed large Warfarin Reinfarction Study (WARIS), which is awaiting publication, will help to define the role of anticoagulant’s after myocardial infarction. The French E.P.S.I.M. (Enquete de Prevention Secondaire de 1’Infarctus du Myocarde) trial (135) attempted to compare anticoagulant therapy with aspirin in postinfarction patients; however, no controlled group was included. At 29 months of follow-up, no significant difference between the two treatment arms emerged with regard to total and cardiac mortality and reinfarction rates. When the trials of aspirin and anticoagulants for secondary prevention of cardiac disease are analyzed together, both treatments appear to convey some protection against death and reinfarction; however, long-term anticoagulant therapy is costly and is associated with a significant risk of bleeding.

Current Recommendations 1) The preferred platelet inhibitor drug in patients with unstable angina is aspirin at a dose of 325 mglday, and its

beneficial effect is still present in the 2 year follow-up period. In addition, a recent trial (107) suggests that high dose anticoagulant therapy with heparin significantly reduces the incidence of infarction and refractory angina in these patients. The short-term combination of aspirin (80 mglday) and low dose warfarin is currently being evaluated. 2) Recent evidence suggests that aspirin (160 mglday) is beneficial in patients with acute myocardial infarction by reducing reinfarction, stroke and early cardiovascular death (29). Short-term administration of anticoagulants may also be beneficial in reducing the incidence of reinfarction and death, although the available data are still controversial. Anticoagulants are particularly effective in reducing left ventricular mural thrombosis and systemic embolism in patients with anterior myocardial infarction. 3) For secondary prevention in survivors of myocardial infarction, aspirin therapy reduces the incidence of vascular mortality, reinfarction and stroke. Although daily doses ranging from 300 to 1,500 mg have been used, the lower dosage is as effective as the larger one, but produces fewer side effects. Available data do not support the use of sulfinpyrazone or dipyridamole. Long-term anticoagulant therapy is also beneficial in reducing reinfarction, but is associated with significant cost, patient discomfort and hemorrhagic side effects. 4) Patients with stable coronary disease or stable angina are commonly treated with aspirin, although its beneficial effects need confirmation by ongoing clinical trials. 5) Aspirin for primary prevention is still controversial. At present, it may be recommended only to individuals at high

JACC Vol. 14, No. 4 October 1989:813-36

PLATELET

risk of developing significant coronary disease, in whom the potential benefits of aspirin outweigh its risks, such as those with hemorrhagic stroke.

Occtusion roles S I month oftcr oDeration

Saphenous Vein Bypass Graft Disease Coronary vein graft disease is the most important contributor to cardiac morbidity and mortality after coronary artery surgery. Occlusion rates are 8% to 18% per distal anastomosis at 1 month postoperatively and 16% to 26% at 12 months (136). At the end of 10 years, up to 50% of vein grafts will be occluded. Vein graft disease can be divided into two main phases: an early postoperative phase of thrombotic occlusion, and a late phase composed of intimal hyperplasia due to smooth muscle cell proliferation, occlusive and nonocclusive graft thrombosis and atherosclerotic plaque formation (137). The late phase of vein graft disease probably represents a continuum of the hyperplastic response to injury with superimposed thrombotic tendency, which may develop at any point during the disease process. Early Phase of Vein Graft Disease The initial endothelial damage to a saphenous vein graft occurs when the vein is removed from the leg during surgery and is suddenly exposed to the high pressure arterial system. Saphenous vein endothelium is injured during harvesting from the leg, surgical handling and suturing and immediately after anastomosis when the vein is abruptly exposed to arterial shear forces (137,138). As blood starts to flow through the graft, platelets, activated after passing through the extracorporeal oxygenator, adhere to areas of damaged endothelium and release their thromobogenic factors. With the understanding that early vein graft occlusion is mainly thrombotic in origin and platelet deposition begins intraoperatively (139), platelet inhibitor drugs are indicated for the prevention of early graft occlusion, and this therapy should be started before or immediately after surgery. Dipyridamole and aspirin. Several studies (54,55,61,62, 140-142) have convincingly demonstrated the importance of initiating platelet inhibitor therapy in the perioperative period, preferably before but no later than 48 h after surgery. Indeed, when therapy was started >48 h after surgery, no reduction in the vein graft occlusion rate was observed (143-146). Experimentally, preoperative treatment with dipyridamole appears to decrease platelet activation by the extracorporeal pump, maintains the platelet count during cardiopulmonary bypass, and does not increase bleeding during surgery (139,147). Accordingly, in a randomized, double-blind, placebo-controlled trial (61), patients received dipyridamole (100 mg four times daily) for 2 days preoperatively, followed by aspirin (325 mg) and dipyridamole (75 mg) three times daily, started 7 hours postoperatively and continued for 1 year. There was no increased incidence of

825

STEIN ET AL. INHIBITOR AGENTS

New occlusion roles ofter

z

-1

I month

Occlusion rates lotc ofteropemtion 42%

I

“1120

PER DISTAL ANASTOMOSIS

PER PATIENT

Figure5. Occlusionrates for all types of vein grafts are shown per distal anastomosis and per patient. Occlusion rates are shown within 1 month, new occlusions beyond 1 month and late after operation (median 1year). Below each percentage, the ratio of occlusion to the total number of distal anastomoses and the ratio of the number of patients with occlusion to the total number of patients is shown. Solid bars depict treated groups; dotted bars depict placebo groups. Reproduced with permission from N Engl J Med (62).

bleeding complications in the treatment group. At vein graft angiography 1 month postoperatively, there was a significant reduction in the incidence of graft occlusion in the treated group from 10% to 2% per distal graft anastomosis and from 22% to 6% per patient (Fig. 5). This was true even in patients at high risk for early graft occlusion. Other antiplatelet agents. In another study (79), ticlopidine (250 mg twice daily) started on the second postoperative day significantly reduced the incidence of vein graft occlusion as assessed angiographically at 10, 180 and 360 days after surgery. In the recently published Veterans Administration Cooperative Study (55), 555 patients were randomized into five groups: aspirin (325 mgiday), aspirin (325 mg three times a day), aspirin (325 mg) plus dipyridamole (75 mg) three times a day, sulfinpyrazone (267 mg three times a day) and placebo. Except for aspirin, which was started 12 h preoperatively, therapy was initiated 48 h before surgery. Graft patency was assessed angiographically between 6 and 60 days (median 9) after surgery. The early graft patency rate was significantly higher in the aspirin treatment groups (92% to 93.5%) as compared with placebo (85%). There was a nonstatistically significant trend toward an improved patency rate with sulfinpyrazone, but this therapy was associated with transient renal insufficiency in 5% of patients. It is important to note that one daily dose of aspirin was as effective as aspirin given three times a day, and that dipyridamole conferred no additional benefit over aspirin alone. Because aspirin was given preoperatively, bleeding during

826

STEIN ET AL. PLATELET INHIBITOR AGENTS

and after surgery, transfusion requirements and reoperation rate were significantly greater in the aspirin-treated patients (55). Late Phase

of Vein Graft Disease

Pathogenesis. This phase probably represents a continuum of the pathologic process that affects vein grafts when exposed to the arterial circulation. Its pathogenesis is most likely multifactorial. As stated before, platelet deposition in areas of endothelial damage occurs as soon as the graft is exposed to arterial shear forces (147,148). Smooth muscle cell proliferation leading to intimal hyperplasia may follow (138,149), probably as a result of chronic endothelial injury and release of mitogenic factors from platelets or perhaps other cells. Occlusive or nonocclusive thrombus formation may occur at any point during the disease process, as documented in surgical specimens (150), autopsy studies (137,138,149) and experimental models (139). Finally, months to years after graft implantation, intimal fibrous plaques consisting of smooth muscle cells, foam cells, collagen and foci of calcification develop (137,149). These fibrous plaques are indistinguishable from atherosclerotic plaques that occur in the native coronary arteries. In a recent study (150) two-thirds of vein grafts removed during a second coronary artery bypass operation showed evidence of mural or occlusive thrombosis. This was particularly prevalent in atherosclerotic grafts and those with aneurysmal dilation, which suggests that late thrombosis is not an uncommon event in chronically injured grafts. Prevention. The available platelet inhibitors do not prevent platelet adherence to the injured endothelium or the release of their mitogenic factors. Thus, smooth muscle cell proliferation and intimal hyperplasia are not affected by these drugs (136). In contrast, antiplatelet agents have been beneficial in reducing the rates of early and late (up to 1 year) vein graft occlusion (62,79). This benefit is most likely a result of the effect of these drugs in limiting superimposed thrombus formation, rather than through a direct effect on the primary occlusive proliferative process. No currently available agent prevents graft atherosclerosis, although control of risk factors such as hyperlipidemia and cigarette smoking may be beneficial (150). In a new trial sponsored by the National Institutes of Health on the prevention of vein graft atherosclerosis, the use of aspirin and lipid-lowering therapy, either alone or in combination, will be tested. Current

Recommendations

1) For the prevention of early thrombotic occlusion of saphenous vein bypass grafts, platelet inhibitor therapy

appears to be mandatory. Because preoperative aspirin is associated with increased intraoperative bleeding (55), we recommend the use of dipyridamole preoperatively (which

JACC Vol. 14, No. 4 October 1989:813-36

prevents activation of platelets by the extracorporeal pump and does not increase bleeding) (61), but we realize that its benefit needs clinical proof. Most importantly, aspirin alone (at a dose of 325 mglday) should be started immediately after surgery and continued for at least 1 year. Postoperative dipyridamole confers no additional benefit to that of aspirin alone (55). 2) It is not yet clear whether aspirin should be continued indefinitely. However, on the basis of previously reviewed available data on native coronary disease, long-term aspirin use for the prevention of coronary artery or graft thrombotic disease is perhaps justified. 3) The control of coronary risk factors is essential. After the first postoperative year, vein graft atherosclerotic disease is conditioned by the risk factors predisposing to native coronary disease. Postangioplasty Occlusion and Restenosis Percutaneous transluminal coronary angioplasty is an important alternative to surgical revascularization in suitable patients with coronary artery disease, and its use has been greatly expanded in the last few years. Fracture or splitting of the stenotic lesion, medial disruption and stretching or expansion of the external diameter of the artery are probably necessary for successful angioplasty (151,152). Endothelial denudation, platelet deposition and mural thrombus formation occur immediately after angioplasty and may lead to acute occlusion and restenosis (153). Acute

Occlusion

The pathogenesis of acute occlusion probably involves one or several mechanisms including formation of large folded intimal flaps as a result of intimal-medial dissection; arterial damage associated with residual stenosis, which facilitates platelet and clotting activation and thrombosis: vasospasm or relaxation of overstretched vessel wall segments, or subintimal plaque hemorrhage, especially after thrombolytic therapy (154). Experimental angioplasty in animals has shown that when arterial injury is mild, it is associated with endothelial denudation and subintimal deposition of platelets. In contrast, extensive arterial wall damage or dissection leads to exposure of media and collagen, which are profoundly thrombogenic despite systemic heparinization (153). Prevention. With regard to preventive therapy for acute occlusion after coronary angioplasty, recent studies strongly suggest that pretreatment with platelet inhibitors such as aspirin alone (155), aspirin plus dipyridamole (78,155,156)or ticlopidine (78) significantly reduces the incidence of acute thrombotic occlusion and periprocedural Q wave infarction. A recent prospective study (157) indicated that aspirin alone was as effective as the combination of aspirin and dipyri-

JACC Vol. 14, No. 4 October 1989:813-36

damole. Although the use of heparin in the prevention of occlusion has not been tested in randomized trials, data derived from uncontrolled trials (158,159) in patients with unstable angina indicate that pretreatment with heparin reduces acute thrombotic complications after angioplasty. Furthermore, there is experimental evidence (160) supporting the use of adequate doses of heparin in the prevention of thrombus formation,

Late Restenosis Restenosis is the major complication after successful angioplasty, with an incidence of 25% to 30%. Although its definition varies among investigators, a number of clinical, anatomic and procedural variables that predispose to restenosis have been found (161,162). Factors associated with a higher restenosis rate include recent onset or crescendo or unstable angina, diabetes mellitus, the presence of a severe preangioplasty stenosis (163), proximal as opposed to distal dilations, lesions in the left anterior descending coronary artery (164), dilation of multiple lesions in the same vessel (165) a high postangioplasty residual stenosis (163,166) and severe vessel injury, with large and complicated intimal dissection (166). The pathogenesis of restenosis is not entirely understood and may involve several different mechanisms. Increased

residual luminal stenosis after dilation produces a high local shear rate and favors platelet deposition and thrombosis (161). Deep arterial injury, with subsequent exposure of librillar collagen and release of tissue thromboplastin, favors platelet aggregation, activation of the coagulation system and thrombus formation (153,167). Furthermore, vascular injury may lead to the release of growth factors from any of four sources: platelets, smooth muscle cells, endothelium and macrophages (95). These growth factors are potent mitogens for smooth muscle cells and fibroblasts. When this proliferative response is excessive, large amounts of connective tissue matrix can be formed, resulting in intimal hyperplasia and recurrent arterial stenosis (153). Finally, the release of vasoactive substances by aggregating platelets (168) loss of endothelium-derived relaxing factor as a consequence of endothelial damage (106) and alteration in the prostaglandin metabolism (169) may result in vasoconstriction and potentially contribute to restenosis. Antithromhotic agents. Factors important in reducing the incidence of restenosis include a technically successful angioplasty, which reduces platelet deposition by limiting the shear rate, and adequate antithrombotic therapy, ideally started before the procedure, to reduce the hemostatic response to arterial wall injury. Unfortunately, results of clinical trials using different antiplatelet drugs and anticoagulant agents aimed at reducing the restenosis rate have been disappointing. In recent clinical studies, aspirin plus dipyridamole (156,170) or ticlopidine (170) failed to reduce the

PLATELET

STElN ET AL. INHIBITOR AGENTS

827

rate of restenosis. Similarly, anticoagulation with Coumadin (crystalline warfarin sodium) for 6 months was of no benefit compared with aspirin (171). Other unsuccessful attempts aimed at reducing restenosis rates have included administration of high dose steroids (172,173) and calcium channel blockers (174.175). Omega-3 fatty acids. The use of omega-3 fatty acids in postangioplasty patients has generated a great deal of interest, but available studies (176-180) have yielded conflicting results. The most carefully conducted of these studies (176) found a significant reduction in restenosis rate, as assessed angiographically. In this trial, fish oils were initiated 7 days before angioplasty, and the effects of therapy on platelet fatty acid concentration were evaluated. Two other trials (177.178), using mostly nonangiographic definitions of restenosis, also found benefit from fish oil therapy. The other two studies (179,180)that employed angiographic follow-up evaluations found no benefit from therapy. Although no definite recommendations can currently be made given available conflicting data, there is evidence to suggest that pretreatment with large doses of omega-3 fatty acids is beneficial in selected patients. Long-term heparin. Heparin has been shown to supress smooth muscle cell proliferation in an animal model of vascular injury (71) and in vitro cell culture (72); however, adequate clinical trials of long-term heparin in postangioplasty patients are lacking. A recent study (181) compared short-term heparin (given for 18 to 24 h) versus placebo after angioplasty. and found no difference in restenosis rate at 6 months. Long-term subcutaneous heparin therapy after angioplasty has not been properly tested in humans. Coronary stents. Recent evidence (182) suggests that mechanical devices such as intracoronary stents may prevent acute vessel closure and, perhaps, reduce the incidence of restenosis in selected patients. Because these results are still preliminary and acute thrombotic occlusion has complicated some of these cases, the widespread use of these devices awaits large scale clinical trials.

Current Recommendations. 1) Until the results of ongoing and future clinical trials are available, the best empiric antithrombotic therapy for the prevention of acute occlusion may be aspirin, started 1 day before angioplasty, followed by a dose of 325 mg 1 h before the procedure and daily thereafter. 2) All patients should receive a bolus of heparin (100 Ulkg) at the beginning of the procedure, followed by an intravenous infusion (at approximately 15 U/kg per h), which should be continued for several hours; the length of heparin therapy will depend on whether a thrombus or a large vessel wall dissection is detected at the end of the procedure. 3) Antiplatelet therapy reduces the incidence of acute occlusion. but its effect on late restenosis is doubtful. A

828

STEIN ET AL. PLATELET INHIBITOR AGENTS

JACC Vol. 14, No. 4 October 1989:813-36

Table 5. Randomized Trials of Platelet Inhibitors Added to Anticoagulant Therapy in Mechanical Prosthetic Valves Study (reference) Sullivan et al. (56) Altman et al. (189) Dale et al. (190) Kasahara (57) Groupe de Recherche PACTE (58) Rajah et al. (59) Chesebro et al. (60)

Therapy

No. of Patients

Embolic Events (%)

Results of Added Therapy

A/C t placebo A/C t dipyridamole

84 79

I4 I

Reduction in embolism (p < 0.01)

A/C A/C t aspirin

65 57

20 5

Reduction in embolism (p < 0.05)

A/C t placebo A/C t aspirin

73 75

I2 2

Reduction in embolism (p < 0.01)

AIC A/C t dipyridamole

39 40

21 5

Favorable trend

AIC MC t dipyridamole

154 136

5 3

Favorable trend

AIC AIC t dipyridamole

87 78

13 4

Favorable trend

AIC AIC t dipyridamole A/C t aspirin

183 I81 170

4 I 4

Reduction in embolism (p < 0.05) No added benefit*

* Significantincrease in gastrointestinal hemorrhage observed. A/C = anticoagulants; PACTE = Prevention des Accidents Thromboemboliques Systemiques Recherche Groupe.

technically good result from the angioplasty itself, with minimal or no postdilation residual stenosis, is important in the prevention of restenosis. 4) Future approaches that may be valuable in reducing the rate of restenosis include omega-3 fatty acid therapy, thrombin inhibitors, blockers of receptors in smooth muscle cells, inhibitors of growth factors that stimulate smooth muscle cell proliferation (183), prostacyclin analogues (68,69) and monoclonal antibodies against platelet membrane receptors and adhesive macromolecules, such as von Willebrand factor. Prosthetic Valve Replacement Thrombosis and thromboembolism. There is a long-term risk of arterial thromboembolism in patients with prosthetic heart valves; progressively fewer patients remain event-free over time. In a long-term study (184) of patients with a mitral or aortic Starr-Edwards prosthesis, only 66% were free of thromboembolic events at 10 years and 58% at 15 years of follow-up. Of the embolic events, 85% were cerebral, resulting in a mortality rate of 10%. Forty percent of patients having inadequate anticoagulation had thromboembolism. Patients with a Bj(irk-Shiley prosthesis have a lower incidence of thromboembolism, but when thrombotic occlusion of the valve occurs, it may lead to acute heart failure. Among the mechanical valves, the St. Jude Medical valve has the lowest, but nevertheless significant, risk of thromboembolism. Although bioprosthetic valves are less thrombogenic, this complication sometimes occurs, particularly in patients not taking anticoagulants with a mitral prosthesis and in those with poor left ventricular function, marked left atrial

enlargement or atria1 fibrillation (185). Overall, there has been a reduction in thromboembolism after valve replacement in recent years, probably because patients are being operated on at an earlier stage in their disease process and new mechanical prosthetic valves have better hemodynamic characteristics. Platelet Inhibitor Agents Mechanical Prostheses

and

Incidence. Studies (185-187) in patients with mechanical valves have consistently shown that appropriate anticoagulation significantly reduces the incidence of valvular thrombosis and embolism. Without long-term anticoagulation, the incidence of thromboembolism increases by two- to sixfold (185). Platelet inhibitors alone have not been found to confer protection against embolism in patients with mechanical prostheses. Several studies (186-188) of aspirin plus dipyridamole in these patients have shown an incidence of thromboembolism as high as 10% per year. Prevention. Because of the persistent risk of thromboembolism in patients with mechanical prostheses who are receiving anticoagulant therapy, the addition of a platelet inhibitor has been prospectively studied (56-60,189,190) (Table 5). The addition of dipyridamole to an oral anticoagulant agent was shown to decrease the incidence of thromboembolism in five trials (56-60). The combination of aspirin and an oral anticoagulant agent was found to be beneficial in two other trials (189,190) but not in a third one (60). However, an increased incidence of gastrointestinal bleeding was found in one study (60) that used aspirin (500 mg/day) plus warfarin. In patients who cannot tolerate dipyridamole,

JACC Vol. 14. No. 4 October 1989:813-36

PLATELET

sulfinpyrazone (200 mg four times daily) may be empirically added to warfarin, although no randomized prospective trials of this combination have been conducted. Uncontrolled studies (83). however, do suggest that this agent is effective.

Platelet Inhibitor Agents and Bioprostheses Although bioprostheses are less thrombogenic than mechanical devices, thromboembolism still occurs, especially in the first 3 months after surgery, more often in patients with a mitral prosthesis and in those with atria1 fibrillation or prior embolism (185). These patients should receive oral anticoagulation postoperatively for 1 to 3 months unless atria1 fibrillation persists, in which case longterm warfarin therapy is required. Long-term aspirin therapy alone has been suggested in patients with a mitral bioprosthesis who do not have any of the risk factors of embolism just mentioned (191). Valve repair instead of replacement in selected patients is rapidly becoming an acceptable alternative and is probably associated with a lower incidence of thromboembolism. Aortic bioprostheses. The appropriate therapy for aortic bioprostheses is still controversial. Although some investigators have recommended warfarin for 3 months, others advocate the use of antiplatelet drugs or no therapy at all because the embolic risk in these patients is low as long as the patient maintains normal sinus rhythm (185). Earlier surgical intervention and better protection of the bioprosthetic material aimed at preventing valvular degeneration have led to increased use of homograft and heterograft bioprostheses. Mitral

bioprostbeses.

Current Recommendations I) All

patients

with a mechanical

prosthetic

heart valve

which should be commenced in the early postoperative period. The dose of warfarin should be strictly controlled to avoid thromboembolic or bleeding complications. Therapy is aimed at prolonging the prothrombin time to 1.5 to 2.0 times control values (international normalized ratio = 3.0 to 4.5). 2) Because of the persistent embolic risk, the addition of dipyridamole may be beneJicia1 in patients at high risk of thromboembolism (those with an old mechanical prosthesis or prior embolism). In patients intolerant of dipyridamole, sulfinpyrazone and warfarin may be used together, with close monitoring of the prothrombin time. The addition of aspirin (>500 mgiday) to an anticoagulant agent is contraindicated because of the significant risk of gastrointestinal bleeding. 3) Patients with a mitral bioprosthesis shouldprobably be require

long-term

on anticoagulant

anticoagulant

therupy for

therapy,

I to 3 months after surgery.

STElN ET AL. INHIBITOR AGENTS

829

Anticoagulation is recommended indefinitely to patients with prior embolic events or atria1 fibrillation. 4) Putients with recurrent thromhoembolism despite adequate antithrombotic therapy should be considered for repeat valve replacement. Cerebrovascular Disease Pathogenesis. Approximately 85% of acute strokes are ischemic in origin, whereas 15% are due to intracranial hemorrhage. Eighty percent of ischemic strokes result from atherosclerotic disease in the carotid or large cerebral arteries by means of embolism of plaque material or platelet-fibrin thromboemboli or through the presence of flow-restricting stenosis that may lead to thrombosis and occlusion. Of all ischemic strokes, only 15% are caused by cardiogenic emboli. These emboli usually arise from thrombus in the left atrium, left ventricular surface and native or prosthetic mitral or aortic valves (192).

Platelet Inhibitor Therapy in Stroke Antiplatelet therapy. The effectiveness of platelet inhibitor agents in the secondary prevention of stroke recurrence has been controversial. One study (52) showed that aspirin had a significant beneficial effect, whereas another large randomized study (193) using 1,500 mgiday of aspirin failed to demonstrate any benefit in the reduction of stroke recurrence or death. In a recent randomized, doubleblind, placebo-controlled trial (1941, 2,500 patients with a recent ischemic neurologic event (60% with stroke, 33% with transient ischemic attack and 6% with reversible ischemic neurologic deficit) were randomized to aspirin (325 mg) plus dipyridamole (75 mg) three times daily. After 2 years. the treated group had a striking 33% reduction in event rate (stroke and death) and a 31% reduction in mortality rate.

A pooled

analysis (131) of 13 randomized

trials of anti-

(including patients with stroke and transient ischemic attacks) clearly showed that treatment reduced the incidence of nonfatal stroke by 22%. nonfatal myocardial infarction by 35% and vascular mortality by 15%. Another platelet inhibitor, ticlopidine, was found to reduce (by 30%) the combined rates of recurrent stroke, myocardial infarction and vascular death in a recent randomized, double-blind, placebo-controlled trial in patients with recent thromboembolic stroke (80). Anticoagulant therapy. With respect to anticoagulant therapy in atherothrombotic stroke, several trials (192) have shown that this approach is potentially dangerous (because of the risk of bleeding) or without benefit and, thus, is not recommended. The use of long-term anticoagulant therapy in patients with cardiogenic embolism is mandatory and will not be discussed further in this review. platelet

therapy

in cerebrovascular

disease

830

STEIN ET AL. PLATELET INHIBITOR AGENTS

JACC Vol. 14, No. 4 October 1989:813-36

Table 6. Randomized Controlled Trials of Aspirin in Transient Ischemic Attacks Study (reference)

Therapy

No. of Patients

Follow-up (months)

Stroke/Death No. (%)

Results of Aspirin Therapy

AITIA-I (195)

Aspirin Placebo

88 90

24

13 (15) 19 (21)

Beneficial trend (small trial)

AITIA-II (196)

Aspirin Placebo

65 60

24

8 (12) 8 (13)

No benefit (small trial)

German (197)

Aspirin Placebo

29 29

24

0 (0) 4 (14)

No benefit (very small trial)

CCSG (86)

Aspirin Sulf/Placebo

290 295

26

46 (16) 68 (23)

Only aspirin was beneficial (p <0.05)

Danish (198)

Aspirin Placebo

101 102

25

21 (21) 17 (17)

No benefit (small trial)

AICLA (52)

Aspirin Placebo

400 204

36

35 (9) 31 (15)

Reduction in event rate (p < 0.02)

ESPS (194)

Aspirin t Dip Placebo

1,250 1,250

24

190(IS) 283 (23)

Marked reduction in event rate (p < 0.001)

UK-TIA (28)

Aspirin Placebo

1,621 814

48

171(II) 109(13)

Reduction in combined vascular event rate (p < 0.05)

AICLA = Accidents Ischemiques Cerebraux lies L’atherosclerose (half of aspirin-treated patients received dipyridamole); AITIA-I = Aspirin in Transient Ischemic Attacks (Medical) Trial; AITIA-II = Aspirin in Transient Ischemic Attacks (Surgical) Trial; CCSG = Canadian Cooperative Study Group; Danish = Danish Cooperative Study; dip = dipyridamole; ESPS = European Stroke Prevention Study (included patients with stroke and transient ischemic attacks); German = German Transient Ischemic Attack Trial; Sulf = sulfmpyrazone; UK-TIA = United Kingdom Transient Ischemic Attack Trial (aspirin doses used: 300 and 1,200mglday).

Platelet Inhibitor Therapy and Transient Ischemic Attacks Numerous studies (28,52,86,194-198) have compared aspirin with placebo or other antithrombotic therapy in patients with transient ischemic attacks (Table 6). Even though the smaller trials (195-198) showed no advantage of aspirin over placebo, the small number of patients limits the significance of these results. More importantly, all four larger trials (28,52,86,194) demonstrated that aspirin significantly reduced the rates of stroke and death (Table 6). Aspirin for prevention. Preliminary results from the large British randomized, controlled trial of aspirin in transient ischemic attacks (UK-TIA) (28) revealed a significant 18% reduction in the combined rate of nonfatal stroke, nonfatal myocardial infarction and death in patients treated with aspirin. However, there was a nonsignificant reduction in the incidence of disabling stroke and vascular death. In this study, 300 and 1,200 mg of aspirin daily were equally effective, but the lower dose was substantially less toxic (28). This evidence, coupled with the results of the pooled analysis of platelet inhibitor trials in secondary prevention of vascular disease (131), clearly suggests that aspirin reduces the incidence of stroke and vascular mortality in patients with transient ischemic attacks. In a recently published randomized study (81) in patients with reversible cerebra1 ischemia, ticlopidine was slightly more effective

than aspirin in preventing fatal and nonfatal strokes. However, ticlopidine’s side effects may limit its usefulness. The use of anticoagulation in transient ischemic attacks is still controversial because both beneficial and harmful trends have been observed (192). Therefore, available data support only the use of aspirin in patients with transient ischemic attacks.

Current Recommendations 1) Aspirin is recommended for patients with transient ischemic attacks for the prevention of vascular events (stroke or myocardial infarction) and vascular mortality. A recent study (28) showed that a daily dose of 300 mg is as effective as 1,200 mg, but less toxic. 2) In patients with a completed stroke, the long-term use of aspirin has been controversial. However, although the recent large European Stroke Prevention Study (194) suggests that aspirin plus dipyridamole is highly beneficial, aspirin alone is probably as effective as the combination with dipyridamole (131). 3) Ticlopidine is proving to be a very efiective agent in patients with cerebrovascular disease, according to recently published clinical trials (80,81). 4) Anticoagulant therapy is not recommended for patients with a transient ischemic attack or completed

stroke.

STEIN ET AL. PLATELET INHIBITOR AGENTS

JACC Vol. 14, No. 4 October

1989:813-36

However, patients with cerebral embolism from a cardiac source should receive anticoagulant therapy.

831

References I. Dalen JE, Hirsh J. Second ACCP national conference on antithrombotic therapy. Chest 1989;95(suppl):lS-169s.

Other Cardiovascular

Conditions

Peripheral vascular disease. The combination of aspirin and dipyridamole reduced the progression of peripheral atherosclerosis in a 2 year study of patients with peripheral vascular disease (199). Other studies (200) suggest a beneficial effect of ticlopidine in patients with chronic arterial insufficiency. Despite encouraging results from some studies, there are no convincing data from properly designed, large trials showing that antithrombotic therapy delays the progression of peripheral vascular disease (201). Arteriovenous cannula. Thrombosis of arteriovenous cannula results in significant morbidity in patients with chronic renal failure on hemodialysis. Anticoagulant agents may decrease the incidence of thrombosis but are hazardous in uremic patients. Two studies using aspirin (160 mg/day) (202) or sulfinpyrazone (82) demonstrated a reduction in the incidence of thrombosis of arteriovenous shunts in these patients. Atrial fibrillation in the absence of valvular heart disease. The incidence of stroke is higher in patients with atrial fibrillation, even in the absence of valvular heart disease. In patients at the highest risk (those with prior embolism, atrial fibrillation of recent onset or left ventricular dysfunction), the incidence of stroke is 5% per year or even higher (192). In these patients. we recommend anticoagulant therapy of moderate intensity. Patients at low risk for embolism (for example, those with lone atria1 fibrillation) do not require anticoagulant therapy. Preliminary evidence from a Danish trial (203) of warfarin, aspirin or placebo in patients with nonvalvular atria1 fibrillation showed that warfarin significantly reduced the rate of embolic events, whereas aspirin was no better than placebo. These findings suggest that in atrial fibrillation, blood stasis and fibrin formation are more important than platelet-mediated events in the development of embolism. Mitral valve prolapse. Patients with mitral valve prolapse, particularly those with a myxomatous valve, are at somewhat higher risk of stroke than is the general population (204,205). Because the risk is low, prophylaxis is not indicated in the absence of additional risk factors for embolism. If an embolic event occurs or there is evidence of recurrent embolism, oral anticoagulation may be empirically instituted, although there is no clear evidence that this is beneficial. We are indebted to Stephanie Lipson Stein for invaluable help in the preparation of the manuscript.

2. Top01 EJ, Califf RM. Symposium on myocardial reperlusion, 1988: practical considerations. J Am Coil Cardiol 1988;12(supplA):lA-92A. 3. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ. Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20. 4. Crowley JG. Pierce RA. The affinityof platelets for subendothelium. Am J Surg 1981;47:529-32. 5. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Human Pathol 1987;18:11l-22. 6. Escolar G, Krumwiede M, White JG. Organization of the actin cytoskeleton of resting and activated platelets in suspension. Am J Pathol 1986;123:86-94. 7. Peerschke EIB. The platelet fibrinogen receptor. Semin Hematol 1985; 22:241-59. 8. Antoniades HN, Hunkapiller MW. Human platelet-derived growth factor (PDGF): aminoterminal aminoacid sequence. Science 1983;220: 963-5. 9. Berk BC, Alexander RW, Brock TA, et al. Vasconstriction: a new activity for platelet-derived growth factor. Science 1986;232:87-90. IO. Deuel TF. Senior RM. Chang D. et al. Platelet factor 4 is chemotactic for neutrophiles and monocytes. Proc Nat1 Acad Sci USA 1981:78:4584-7. I I. Badimon L, Badimon JJ, Turitto VT, Chesebro JH, Fuster V. Mechanism of arterial thrombosis: platelet thrombus deposition in areas of stenosis (abstr). Circulation 1987;76(supplIV):IV-102. I?. Shattil SJ. Brass LP. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem 1987:262:992-1000. 13. Caller BS. Activation affects access to the platelet receptor for adhesive plycoproteins. J Cell Biol 1986;103:451-6. 14. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300: 1142-7.

IS. Haslam RJ, Davidson MML, Fox JEB. Lynham JA. Cyclic nucleotides in platelet function. Thromb Haemost 1978:40:232-40. 16. Walsh PN, Schmaier AH. Platelet-coagulation protein interactions. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia: Lippincott. 1987:689-709. 17. Ofosu FA. Cerskus AL, Hirsh JA, et al. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tissue factor. Br J Haematol 1984;57:229-38. 18. McNeely TB, Griffith MJ. The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation. Blood 1985;65:1226-3I, 19. Van Hinsbergh VWM. Bertina RM. van Wijngaarden A, et al. Activated protein C decreases plasminogen activator-inhibitor activity in endothehal cell-conditioned medium. Blood 1985:65:44C51. 20. Cohen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980:43:7749. 21. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984;74:1465-72. 22. Mimuro J. Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type I plasminogen activator inhibitor. Blood 1987;70:721-8. 23. Tschopp TB. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen librils: an assessment of platelet adhesion and deposited platelet mass by morphometry and “Cr-1abelling. Thromb Res 1977; I1:619-32. 24. Clowes AW. Karnovsky MJ. Failure of certain antiplatelet drugs to affect myointimal thickening following arterial endothelial injury in the rat. Lab Invest 1977:36:452&l.

832

STEIN ET AL.

JACC Vol. 14, No. 4

PLATELET INHIBITOR AGENTS

October 1989:813-36

25. Roth GL, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:62432.

46. FitzGerald GA. Dipyridamole. N Engl J Med 1987;316:1247-57.

26. Kyrle PA, Eichler HG, Jager U, Lechner K. Inhibition of prostacyclin and thromboxane A, generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation 1987;75:1025-9.

48. Weily HS, Steele PP, Davies H, Pappas G, Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med 1974;290:534-7.

21. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med I983;309:396-403. 28. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988;296:316-20. 29. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:34%0. 30. Graham DY, Smith LJ. Aspirin and the stomach. Ann Intern Med 1986;104:390-8. 31. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-75. 32. Neri Semeri GG, Castellani S. Platelet and vascular prostaglandins: pharmacological and clinical implications. In: Born GVR, Neri Serneri GG, eds. Antiplatelet Therapy: Twenty Years’Experience. Proceedings of a European Conference. Amsterdam: Elsevier (Excerpta Medica), 1987:37-51. 33. Friedman PL, Brown EJ, Gunther S, et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary artery disease. N Engl J Med 1981;305:1171-5. 34. Kromhout D, Bosschieter EB, Coulander CDL. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-9. 35. Shekelle RB, Missel L, Paul 0, Shryock AM, Stamler 3. Fish consumption and mortality from coronary heart disease (letter). N Engl J Med 1985;313:820. 36. Von Schacky C. Prophylaxis of atherosclerosis with marine omega-3 fatty acids: a comprehensive strategy. Ann Intern Med 1987;107:890-9. 37. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988;318:549-57. 38. FitzGerald GA, Reilly LA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72:1194-201. 39. Mullane KM, Fornabaio D. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism. Circ Res 1988;62:668-78. 40. Reuben SR, Kuan P, Cairns T, Gysle OH. Effects of dazoxiben and exercise performance in chronic stable angina. Br J Clin Pharmacol 1983;15(suppl1):83%S.

47. Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970;283:1302-5.

49 Harker LA. Platelet survival time: its measurement and use. Prog Hemost Thromb 1978;4:321-47. 50. Hanson SR, Harker LA, Bjornsson TD. Effect of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985;75:1591-9. 51. The Persantine-Aspirin Reinfarction Study Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:44%1. 52. Bousser MG, Eschwege E, Haugenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14:5-14. 53. American-Canadian Cooperative Study Group. Persantine-aspirin trial in cerebral ischemia. Part II. Endpoint results. Stroke 1985;16:406-15. 54. Brown BG, Cukingnan RA, DeRouen T, et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 1985;72:138-46. 55. Goldman S, Copeland J, Mortiz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-32. 56. Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971;284:1391-4. 57. Kasahara T. Clinical effect of dipyridamole ingestion after prosthetic heart valve replacement-especially on the blood coagulation system. J Jpn Assoc Thorac Surg 1977;25:1007-21. 58. Groupe de Recherche PACTE. Prevention des accidents thromboemboliques systemiques chez les porteurs de prosthesis valvulaires artificielles: essai cooperatif controle du dipyridamole. Coeur 1978;9:91549. 59. Rajah SM, Sreeharan N, Joseph A, et al. A prospective trial of dipyridamole and warfarin in heart valve patients (abstr). Acta Therapeutica 1980;6(suppl93):54. 60. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51:1537-41. 61. Chesebro JH, Clements IP, Fuster V, et al. A platelet inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982;307:73-8. 62. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984;310:2w14.

41. Thaulow E, Dale J, Myhre E. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. Am J Cardiol 1984;53:1255-8.

63. Weksler BB. Prostaglandins and vascular function. Circulation 1984; 7O(supplllI):III-63-71.

42. Saussy DL Jr, Mais DE, Knapp DR. Halushka PV. Thromboxane A, and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation 1985;72:1202-7.

64. Coppe D, Sobel M, Seavans L, Levine F, Salzman E. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;81:274-8.

43. Gresele P, Van Houtte E, Amout J, Deckmyn H, Vermylen J. Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy (letter). Thromb Haemost 1984;52:364.

65. Smith MC, Danviriyasup K, Crow JW, et al. Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med 1982;73:669-78.

44. Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978;1:1286-9. 45. Crutchley DJ, Ryan US, Ryan JW. Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. J Clin Invest 3980;66:29-35.

66. Uchida Y, Hanai T, Hasewaga K, Kawarnura K, Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv Prostaglandin Thromboxane Leukotriene Res 1983;11:377-83. 67. Sharma B, Wyeth RP, Heinemann FM, Bissett JK. Addition of intracoronary prostaglandin E, to streptokinase improves thrombolysis and left ventricular function in acute myocardial infarction (abstr). J Am Coil Cardiol l988;ll(suppl A):l04A.

JACC Vol. 14. No. 4 October 1989:813-36

STEIN ETAL. PLATELET INHIBITOR AGENTS

833

68. Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin. and prostaglandin E, on human platelet function. J Lab Clin Med 1987;109:184-90.

91. Brown RIG, Aldridge HE, Schwartz L, Henderson M, Brooks E, Coutanche M. The use of dextran-40 during percutaneous transluminal coronary angioplasty: a report of three cases of anaphylactoid reactions-one near fatal. Cathet Cardiovasc Diagn 1985;11:591-5.

69. Raizner A, Hollman J, Demke D, Wakefield L. Beneficial effects of ciprostene in PTCA: a multicenter, randomized, controlled trial (abstr). Circulation 1988:78(supplII):ll-290.

92. Hanson SR, Pareti FL Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein Ilb/llIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988;81:149-58.

70. Salzman EW. Rosenberg RD. Smith MH. Lindon JN. Favreau L. Effect of heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73.

93. Gold HK, Caller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPllbl llla antibody in a canine preparation. Circulation 1988:77:670-7.

71 Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977:265:625-6. 72 Reilly CF, Fritze LMS. Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol 1986; l29:ll-9. 73 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-t.-prolyl+-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988:85:3184-8. 74 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute plateletthrombus deposition during angioplasty in pigs. Circulation 1989; 791657-65. 75 Lee H, Paton KC. Ruan C. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets (abstr). Thromb Haemost lY81;46:67. 76 O’Brien JR. Ticlopidine. a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983;13:1-54. 77 Violi F, Scrutinio D, CimminielloC, et al. S.T.A.I. (Study of Ticlopidine in Unstable Angina) (abstr). J Am Coll Cardiol 1989;13(supplAk238A. 78 White CW, Chaitman B, Lassar TA, et al. Antiplatelet agents are effective in reducing the immediate complications of PTCA: results from the ticlopidine multicenter trial (abstr). Circulation 1987:76(supplIV): IV-400. 79 Limet R, David JL, Magotteaux P, Larock MP. Rigo P. Prevention of aorta-coronary bypass graft occlusion. J Thorac Cardiovasc Surg 1987: 94:773-83. 80. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20. 81. Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7. 82. Kaegi A, Pineo GF. Shimizu A, Trivedi H, Hirsh J, Gent M. Arteriovenous-shunt thrombosis: prevention by sulfinpyrazone. N Engl J Med 1974;290:304-6. 83. Steele PP, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves: relationship of clinical effectiveness to alteration of platelet survival time. Circulation 1979:60:910-3. 84. Report from the Anturane Reinfarction Italian Study. Sullinpyrazone in post-myocardial infarction. Lancet 1982;1:237-42.

94. Badimon L. Badimon JJ. Chesebro JH, Fuster V. Inhibition of thrombus formation: blockage of adhesive glycoprotein mechanisms versus blockage of the cyclooxygenase pathway (abstr). J Am Coil Cardiol 1988; I I(suppl A):30A. 95. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986;314:488-500. 96. Fuster V. Griggs TR. Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis. Prog Hemost ‘Thromb198618: 159-83. 97. ‘The Steering Committee of the Physicians’ Health Study Research Group. The Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’health study. N Engl J Med lY89:321:12%35. 98. Peto R. Gray R. Collins R, et al. A randomized trial of the effects of prophylactic daily aspirin among male British doctors. Br Med J 1988; 296:313-6. 98a.Fuster V. Cohen, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989;32l:l29-35. 99. Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107necropsy patients. Am J Med 1972;52:425-43. 100. Bini A, Fenoglio JJ, Mesa-Tejada R. Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrimogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis 1989:9:109-21. lOOa.CheseboroJH, Webster MWI, Smith HC, et al. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation (abstr). Circulation 1989(in press). 101. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathological correlates. Circulation 1982:66:31620. IO?. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5:609-16. 103. Sherman CT. Litvak F, Grundfest W. et al. Coronary angioscopy in patients with unstable angina. N Engl J Med 1986;315:913-9.

85. Baur HR. Van Tassel RA, Pierach CA, Gobel RL. Effects of sulftnpyrazone on early graft closure after myocardial revascularization. Am J Cardiol 1982;49:420-4.

104. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985:53:363-73.

86. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-9.

105. Falk E. Unstable angina with fatal outcome, dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in lotal vascular occlusion. Circulation 1985;71:69%708.

87. Harker LA, Fuster V. Pharmacology of platelet inhibitors. J Am Coll Cardiol 1986;8(supplB):21&32B. 88. Oberg M, Hedner U, Bergentz SE. Effect of dextran 70 on factor VIII and platelet function in von Willebrand’s disease. Thromb Res 1978: 12:629-34. 89. Weiss HJ. The effect ofclinical dextran on platelet aggregation, adhesion and ADP release in man: in vivo and in vitro studies. J Lab Clin Med 1967:69:37-46. 90. Swanson KT, Vlietstra RE. Holmes DR. et al. Efficacy of adjunctive dextran during percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;54:447-8

106. Ludmer PL. Selwyn AP, Shook TL. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-551. 107. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319: 1105-l I 108. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1:1225-8. 109. Ambrose JA, Hjemdahl-Monsen CE. Borrico S. Gorlin R, Fuster V.

834

STEIN ET AL. PLATELET INHIBITOR AGENTS

JACC Vol. 14, No. 4 October 1989:813-36

Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol 1988;61:244-7.

129. The Anturane Reinfarction Trial Research Group. Suhinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250-6.

110. Gibson RS, Beller GA, Gheorghiade M, et al. The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. Circulation 1986;73:1186-98.

130. Klimt CR, Knatterud GL, Stamler J, Meier P, and the PersantineAspirin Reinfarction Study Research Group. Part II. Secondary coronary prevention with Persantine and aspirin. J Am Coil Cardiol 1986; 7:251-69.

111. Timmis AD, Griffin B, Crick JCP, Nelson DJ, Sowton E. The effects of early coronary patency on the evolution of myocardial infarction: a prospective arteriographic study. Br Heart J 1987;58:345-51.

131. Antiplatelet Trialists’Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;2%:320-31.

112. DeWood M, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction. N Engl J Med 1986;315:417-23.

132. Second Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. An assessment of long-term anticoagulant administration after cardiac infarction. Br Med J 1964;2:837-43.

113. Freifeld AC, Shuster EH, Bulkley BH. Nontransmural versus transmural myocardial infarction: a morphologic study. Am J Med 1983;75:42332.

133. Ebert RV, Borden CW, Hipp HR, et al. Long-term anticoagulant therapy after myocardial infarction: final report of the Veterans Administration Cooperative Study. JAMA 1969;207:2263-7.

114. Brown BG, Gallery CA, Badger RS, et al. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 1986;73:653-61.

134. Report of the Sixty Plus Reinfarction Study Research Group. A doubleblind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-93.

115. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coil Cardiol 1988;12:56-62. 116. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary arteriography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease. Circulation 1988;78:1157-66.

135. The E.P.S.I.M. Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-8. 136. Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation 1986;2:227-32. 137. Bulkley BH, Hutchins GM. Accelerated “artherosclerosis”: a morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation 1977;55:163-9.

117. Meade TW, Brozovic M, Chakrabarti RR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.

138. Unni KK, Kottke BA, Titus JL, Frye RL, Wallace RB, Brown AL. Pathologic changes in aortocoronary saphenous vein grafts. Am J Cardiol 1974;34:52&32.

118. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988;115:776-80.

139. Josa M, Lie JT, Bianco RL, Kaye MP. Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol 1981;47:1248-54.

119. Report of the Working Party on Anticoagulation Therapy in Coronary Thrombosis to the Medical Research Council. Assessment of short-term anticoagulation administration after cardiac infarction. Br Med J 1%9; 11335-42.

140. Lorenz RL, Weber M, Kotzur J, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mgldaily): effects on platelet aggregation and thromboxane formation. Lancet 1984;1:1262-4.

120. Drapkin A, Merskey C. Anticoagulation therapy after acute myocardial infarction: relation of therapeutic benefit to patient’s age, sex and severity of infarction. JAMA 1972;222:541-8. 121. Veterans Administration Hospital Investigators. Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA 1973;225:724-9. 122. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352-7. 123. Chalmers TC, Matta RJ, Smith H, Kunzler A-M. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6. 124. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974;1:43&40. 125. Coronary Drug Project Group. Aspirin in coronary heart disease. J Chronic Dis 1976;29:625-42. 126. Breddin K, Loew D, Lechner K, Oberla K, Walter E. The GermanAustrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980;62(supplV):V-63-72. 127. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979;2:1313-5. 128. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-9.

141. Rajah SM, Salter MCP, Donaldson DR, et al. Acetylsahcylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovast Surg 1985;89:373-7. 142. Mayer JE, Lindsay WG, Castaneda W, Nicoloff DM. Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. Ann Thorac Surg 1981;31:204-10. 143. Brooks N, Wright J, Sturridge M, et al. Randomized placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J 1985;53:201-7. 144. McEnany MT, Salzman EW, Mundth ED, et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 1982;83:81-9. 145. Pantely GA, Goodnight SH, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronaryartery bypass: a controlled randomized study. N Engl J Med 1979; 301:9624. 146. Sharma GVRK, Khuri SF, Josa M, Folland ED, Parisi AF. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation 1983;68(supplII):II-218-21. 147. Fuster V, Dewanjee MK, Kaye MP, Josa M, Metke MD, Chesebro JH. Noninvasive radioisotopic technique for detection of platelet deposition in coronary artery bypass grafts in dogs and its reduction with platelet inhibitors. Circulation 1979;60:1508-12. 148. Dewanjee MK, Tago M, Josa M, Fuster V, Kaye MP. Quantification of platelet retention in aortocoronary femoral vein bypass graft in dogs treated with dipyridamole and aspirin. Circulation 1984;69:350-6. 149. Lie JT, Lawrie GM, Morris GC. Aortocoronary bypass saphenous vein graft atherosclerosis. Am J Cardiol 1977;40:90&14.

JACC Vol. October

14, No. 4 1989:813-36

150. Solymoss BC. Nadeau P, Millette D. Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988:78(supplI):&14&3. 151. Faxon DP, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis 1982;2:125-33.

STEIN ET AL. PLATELET INHIBITOR AGENTS

835

randomized placebo-controlled multicenter trial (abstr). Circulation 1987;76(supplIV):IV-213. 171. Thornton MA, Gruentzig AR, Hollman J. King SB, Douglas JS. Coumadin and aspirin in the prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984;69:721-7.

152. Block PC. Myler RK. Stertzer S, Fallon JT. Morphology after transluminal angioplasty in human beings. N Engl J Med 19X1:305:382-5.

172. Rose TE, Beauchamp BG. Short term, high dose steroid treatment to prevent restenosis in PTCA (abstr). Circulation 1987;76(supplIV): (V-371.

153. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 19X5:57:105-12.

173. Pepine CJ. Hirshfeld JW, Macdonald RG, et al. A controlled trial of corticosteroids to prevent restenosis following coronary angioplasty (abstr). Circulation 1988;78(supplII):II-291.

154. Wailer BF. “Crackers, breakers, stretchers, drillers, scrapers, shavers. burners. welders and melters”: the future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment. J Am Coll Cardiol 1989:13:969-87.

174. Faxon DP, Sanborn TA, Haudenschild CC, et al. Effect of nifedipine on restenosis following experimental angioplasty (abstr). Circulation 1984; 7O(suppl):II-175.

155. Barnathan ES, Schwartz JS, Taylor L. et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987:76:125-34. 156. Schwartz L, Bourassa MC. Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9. 157. Lembo NJ. Black AJ, Roubin GS, et al. Does the addition of dipyridamole to aspirin decrease acute coronary angioplasty complications? The results of a prospective randomized clinical trial (abstr). J Am Coll Cardiol 1988:13(supplA):237A. 158. Lukas MA, Deutsch E. Laskey WK. Beneficialeffect of heparin therapy on PTCA outcome in unstable angina (abstr). J Am Coll Cardiol l988;ll(suppl A):l32A. 159. Pow TK, Varricchione TR. Jacobs AK. et al: Does pretreatment with heparin prevent abrupt closure following PTCA? (abstr). J Am Coll Cardiol 1988:lI(suppl A):238A. 160. Heras M, Chesebro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988:78:654-60. 161. Kent KM. Restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988:6l(supplG):67G-70G. 162. McBride W, Lange RA. Hillis LD. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 1988:31X: 1734-7. 163. Block PC. Percutaneous transluminal coronary angioplasty: role in the treatment of coronary artery disease. Circulation 1985:72(supplVI: V-161-S.

175. Corcos T. David PR. Val PG, et al. Failure of diltiazem to prevent restenosis after PTCA. Am Heart J 1985:109:926-31. 176. Dehmer GJ. Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988;319:733-40. 177. Milner MR. Gallino RA, Lefingwell A. et al. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1989;64:294-9. 178. Slack JD. Pinkerton CA, Vantaseel J. et al. Can oral fish oil supplement minimize restenosis after percutaneous transluminal coronary angioplasty? (abstr). J Am Coll Cardiol 1987;9(supplA):64A. 179. Grigg LE. Kay TWH, Valentine PA. et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary restenosis after angioplasty. J Am Coll Cardiol 19X9:13:665-72. 1x0. Reis GJ. Sipperly ME. Boucher TM, et al. Results of a randomized, double-blind, placebo-controlled trial of fish oil for the prevention of restenosis after PTCA (abstr). Circulation 1988;78(supplII):II-291. 1x1. Ellis SG. Roubin GS, Wilentz J, Douglas JS, King SB. Effect of l8- to 24-hourheparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989:177:777-X2. 1x2. Sigwart U. Puel J, Mirkovitch V, Joffre K, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987:316:701-6. 183. Liu MW. Roubin GS, Robinson KA. Black AJ. King SB. Trapidil (triazolo-pyrimidine). a platelet-derived growth factor antagonist in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit (abstr). Circulation 1988;7X(supplII):II-290.

164. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986:73:710-7.

1x4. Fuster V, Pumphrey CW, McGoon MD. Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic StarrEdwards prostheses: a IO-19 year follow-up. Circulation 1982;66(suppl l):I-157-61.

165. Roubin GS. King SB, Douglas JS. Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience. Am J Cardiol 1987;6O(supplB):39B-438.

1x5. Edmunds LH. Thrombotic and bleeding complications of prosthetic heart valves. .4nn Thorac Surg 1987;44:430-45.

166. Guiteras Val P, Bourassa MG, David PR, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: the Montreal Heart Institute experience. Am J Cardiol 1987:6O(suppl B):SOB-5B. 167. Lam JYT. Chesebro JH, Steele PM. et al. Deep arterial injury during experimental angioplasty: relations to a positive indium-I I l-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol l986;8:1380-6, 168. Lam JYT. Chesebro JH. Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 1987;75:2426. 169. Cragg A, Einzig S. Castaneda-Zuniga W, et al. Vessel wall arachidonate metabolism after angioplasty: possible mediators of postangioplasty vasospasm. Am J Cardiol 1983:51:1441-5. 170. White CW, Knudson M, Schmidt D, et al. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: results from a

186. Chaux A. Czer LSC, Matloff JM. et al. The St. Jude bileaflet valve prosthesis: a 5 year experience. J Thorac Cardiovasc Surg 1984; X8:706-17. 1x7. Myers ML. Lawrie GM, Crawford ES. et al. The St. Jude valve prosthesis: analysis of the clinical results in Xl5 implants and the need for systemic anticoagulation. J Am Coil Cardiol 1989;13:57-62. 188. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 19X5:72:1059-63. 189. .4ltman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976;72:127-9. 190. Dale J. Myhre E. Storstein 0, et al. Prevention of arterial thromboemholism with acetylsalicyclic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977:94:101-lI.

836

STEIN ET AL. PLATELET INHIBITOR AGENTS

191. Nunez L, Gil Aguado M, Larrea JL, et al. Prevention of thromboembo-

lism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 1984;37:84-7. 192. Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG.

Antithrombotic therapy in cerebrovascular disorders. Chest 1989; 95(suppl):14os-55s. 193. A Swedish Cooperative Study. High dose acetylsalicylic acid after

cerebral infarction. Stroke 1987;18:325-34. 194. The ESPS Group. The European Stroke Prevention Study: principal

end-points. Lancet 1987:2:1351-4. 195. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of

aspirin in cerebral ischemia. Stroke 1977:8:301-16. 1%. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of

aspirin in cerebral ischemia: part 11. Surgical group. Stroke 1978; 93309-18. 197. Ruether R, Domdorf W. Aspirin in patients with cerebral ischemia and

normal angiograms or non-surgical lesions: the results of a double-blind trial. In: Breddin K, Domdorf W, Loew D, Marx R, eds. Acetylsalicylic Acid in Cerebral lschemia and Coronary Heart Disease. Stuttgart: Schattauer Verlag, 1978:97-106. 198. Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in

the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish cooperative study. Stroke 1983;14:15-22.

JACC Vol. 14, No. 4 October 1989:813-36

199. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet 1985; 1:415-21. 200. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive disease: a double-blind study versus placebo. Angiology 1982;33:357-67. 201. Clagett GP, Genton E, Salzman EW. Antithrombotic therapy in peripheral vascular disease. Chest 1989;95(suppl): 128S-39s. 202. Hatter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301:577-9. 203. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;1:175-9. 204. Barnett HJM, Jones MW, Boughner DR, Kostuk WJ. Cerebral ischemic events associated with prolapsing mitral valve. Arch Neurol 1976; 331777-82. 205. Nishimura RA, McGoon MD, Shub C, Miller FA, Ilstrup DM, Tajik AJ. Echocardiographically documented mitral valve prolapse: long-term follow-up of 237 patients. N Engl J Med 1985;313:1305-9.